<PAGE>
SCHEDULE 14A
(RULE 14A-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14 A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES
EXCHANGE ACT OF 1934 (AMENDMENT NO. )
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement [_] Confidential, for Use of the
Commission Only (as permitted by
rule 14a-6(e)(2))
[X] Definitive Proxy Statement
[_] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-11(c) or Section 240.14a-12
TRIAD HOSPITALS, INC
-------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
-------------------------------------------------------
(Name of Person(s) Filing Proxy Statement)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
- -------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
- -------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is
calculated and state how it was determined):
- -------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
- -------------------------------------------------------------------------
(5) Total fee paid:
- -------------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
- -------------------------------------------------------------------------
[_] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number, or
the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
- -------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
- -------------------------------------------------------------------------
(3) Filing Party:
- -------------------------------------------------------------------------
(4) Date Filed:
- -------------------------------------------------------------------------
<PAGE>
TRIAD HOSPITALS, INC.
13455 Noel Road, 20th Floor
Dallas, Texas 75240
----------------
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
May 23, 2000 at 10:00 a.m., local time
----------------
To our Stockholders:
The 2000 Annual Meeting of Stockholders of Triad Hospitals, Inc. (the
"Company") will be held at the Westin Park Central Hotel, 8051 LBJ Freeway,
Dallas, Texas, on Tuesday, May 23, 2000 beginning at 10:00 a.m., local time.
The meeting will be held for the following purposes:
1. To elect three directors to serve until the 2003 annual meeting of
stockholders and to elect one director to serve until the 2001 annual
meeting of stockholders, or until their respective successors shall have
been duly elected and qualified.
2. To ratify the appointment of PricewaterhouseCoopers LLP as our
independent auditors.
3. To act upon a proposal to approve the Company's 1999 Long-Term
Incentive Plan.
4. To act upon a proposal to approve the Company's Employee Stock
Purchase Plan.
5. To transact such other business as may properly come before the
meeting.
Stockholders of record at the close of business on April 14, 2000 are
entitled to notice of, and to vote at, the Annual Meeting. A complete list of
the stockholders entitled to vote at the Annual Meeting will be available for
examination by any stockholder at our executive offices, during ordinary
business hours, for a period of at least ten days prior to the Annual Meeting.
You are cordially invited to be present. This will be our first stockholder
meeting as a publicly-owned company. Stockholders who do not expect to attend
in person are requested to sign and return the enclosed form of proxy in the
envelope provided. At any time prior to their being voted, proxies are
revocable by written notice to the Secretary of the Company or by voting at the
meeting in person.
By order of the Board of Directors
DONALD P. FAY
Executive Vice President, General
Counsel
and Secretary
April 24, 2000
<PAGE>
TRIAD HOSPITALS, INC.
13455 Noel Road, 20th Floor
Dallas, Texas 75240
PROXY STATEMENT
----------------
ANNUAL MEETING OF STOCKHOLDERS
To be held May 23, 2000
----------------
This statement is furnished in connection with the solicitation of proxies
by the Board of Directors of Triad Hospitals, Inc. ("Triad" or the "Company")
from holders of the Company's outstanding shares of common stock entitled to
vote at the 2000 Annual Meeting of Stockholders of the Company (and at any and
all adjournments thereof) (the "2000 Annual Meeting") for the purposes referred
to below and set forth in the accompanying Notice of Annual Meeting of
Stockholders. Stockholders of record at the close of business on the record
date, April 14, 2000, are entitled to notice of and to vote at the 2000 Annual
Meeting. This Proxy Statement and the accompanying proxy materials are first
being mailed to stockholders on or about April 24, 2000.
GENERAL INFORMATION ABOUT THE MEETING
Voting at the Annual Meeting
As of the record date, there were approximately 34,013,348 shares of the
Company's common stock outstanding and entitled to vote. Each share of common
stock entitles the holder to one vote on all matters presented at the Annual
Meeting.
The presence at the meeting, in person or by proxy, of at least a majority
of the outstanding shares of common stock entitled to vote is necessary to
constitute a quorum to transact business at the 2000 Annual Meeting. The
affirmative vote of a plurality of the shares of common stock represented at
the 2000 Annual Meeting, in person or by proxy, is necessary for the election
of directors. Stockholders will determine any other matters submitted to them
by a majority of the votes present or represented by proxy and entitled to
vote.
A stockholder who is present or represented by proxy at the 2000 Annual
Meeting will be counted for purposes of determining if a quorum exists even if
the stockholder abstains from voting. Votes withheld from the election of any
nominee for director and abstentions from any other proposal will not be
counted in the number of votes cast on any matter. If a broker does not receive
voting instructions from the beneficial owner of shares on a particular matter
and indicates on the proxy that it does not have discretionary authority to
vote on that matter, those shares will be considered as present and entitled to
vote with respect to that matter, but will not be counted in the number of
votes cast "for" or "against" the matter.
Shares of common stock represented by properly executed proxies will be
voted at the 2000 Annual Meeting according to the directions marked on the
proxies, unless they have previously been revoked. If the stockholders do not
give directions on the proxies, the proxy holder will vote them for the
election of each nominee named under "Election of Directors", for the
ratification of PricewaterhouseCoopers LLP as our independent auditors, for the
approval of the Company's 1999 Long-Term Incentive Plan described under
"Approval of 1999 Long-Term Incentive Plan," and for the approval of the
Employee Stock Purchase Plan described under "Approval of Employee Stock
Purchase Plan." Such proxy may be revoked by the person executing it at any
time before it is voted by filing with our Corporate Secretary either a notice
of revocation or a duly executed proxy bearing a later date. The proxy holder's
powers will be suspended if you attend the meeting in person and so request,
although attendance at the meeting will not by itself revoke a previously
granted proxy.
<PAGE>
Solicitation Expenses
Expenses in connection with the solicitation of proxies will be borne by the
Company. Brokers, custodians and fiduciaries will be requested to transmit
proxy material to the beneficial owners of common stock held of record by such
persons, at the expense of the Company. The Company has retained Corporate
Investor Communications, Inc. to aid in the solicitation of proxies, and for
its services the Company expects to pay fees of approximately $8,000 plus
expenses.
STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth information regarding the beneficial
ownership of Triad common stock as of March 31, 2000, by each person known by
Triad to be a beneficial owner of 5% or more of the outstanding Triad common
stock and beneficial ownership of Triad common stock by each director and named
executive officer and all directors and executive officers as a group:
<TABLE>
<CAPTION>
Number Percent
Name of Beneficial Owner ofShares(1)(2) ofClass
- ------------------------ -------------- -------
<S> <C> <C>
Triad Hospitals, Inc. Retirement Savings Plan.......... 3,000,000 8.8%
Blue Ridge Limited Partnership, JAG Holdings LLC, and
John A. Griffin(3).................................... 1,790,000 5.3%
Capital Group International, Inc. and Capital Guardian
Trust Company(4)...................................... 1,759,000 5.2%
Vanguard Windsor Funds(5).............................. 2,170,789 6.4%
FMR Corp., Edward C. Johnson 3d and Abigail P. John-
son(6)................................................ 2,486,463 7.3%
Greenlight Capital, L.L.C., David Einhorn and Jeffrey
A. Keswin (7)......................................... 2,977,000 8.8%
Wellington Management Company, LLP(8).................. 4,083,921 12.1%
James D. Shelton(9).................................... 676,828 2.0%
Thomas G. Loeffler, Esq................................ 1,565 *
Thomas F. Frist III.................................... 320,857 *
Marvin Runyon.......................................... 1,565 *
Michael J. Parsons(9).................................. 187,702 *
Nicholas J. Marzocco(9)................................ 85,098 *
Christopher A. Holden(9)............................... 82,624 *
Donald P. Fay(9)....................................... 75,480 *
Uwe E. Reinhardt, Ph.D................................. 0 *
Dale V. Kesler......................................... 1,282 *
Gale Sayers............................................ 1,000 *
William R. Huston(9)................................... 89,844 *
W. Stephen Love(9)..................................... 61,785 *
Wayne G. McAlister(9).................................. 58,979 *
Burke W. Whitman(9).................................... 260,660 *
All Directors and Executive Officers as a Group (15
persons)(9)........................................... 1,905,269 5.5%
</TABLE>
- --------
* Less than one percent.
(1) Unless otherwise indicated, each stockholder shown on the table has sole
voting and investment power with respect to the shares beneficially owned.
The number of shares shown does not include the interest of certain persons
in shares held by family members in their own right.
(2) Each named person or group is deemed to be the beneficial owner of
securities which may be acquired within 60 days through the exercise or
conversion of options, warrants and rights, if any, and such securities are
deemed to be outstanding for the purpose of computing the percentage
beneficially owned by such person or group. Such securities are not deemed
to be outstanding for the purpose of computing the percentage beneficially
owned by any other person or group. Accordingly, the indicated number of
shares includes shares issuable upon conversion of convertible securities
or upon exercise of options (including employee stock options) held by such
person or group.
2
<PAGE>
(3) The ownership given for Blue Ridge Limited Partnership, JAG Holdings LLC
and John A. Griffin is based on information contained in the Schedule 13G/A
dated February 14, 2000, filed with the Commission by Blue Ridge Limited
Partnership in respect of its beneficial ownership of Triad Hospitals, Inc.
common stock. The address of Blue Ridge Limited Partnership is 660 Madison
Avenue, 20th floor, New York, New York 10021.
(4) The ownership given for Capital Group International, Inc. and Capital
Guardian Trust Company is based on information contained in the Schedule
13G dated February 10, 2000, filed with the Commission by Capital Group
International, Inc. in respect of its beneficial ownership of Triad
Hospitals, Inc. common stock. The address of Capital Group International,
Inc. is 11100 Santa Monica Blvd., Los Angeles, California 90025.
(5) The ownership given for Vanguard Windsor Funds is based on information
contained in the Schedule 13G dated February 8, 2000, filed with the
Commission by Vanguard Windsor Funds in respect of its beneficial ownership
of Triad Hospitals, Inc. common stock. The address of Vanguard Windsor
Funds is P.O. Box 2600, V37, Valley Forge, Pennsylvania 19482.
(6) The ownership given for FMR Corp., Edward C. Johnson 3d and Abigail P.
Johnson is based on information contained in the Schedule 13G dated
February 1, 1999, filed with the Commission by FMR Corp. in respect of its
beneficial ownership of Columbia/HCA common stock. The address of FMR Corp
is 82 Devonshire Street, Boston, Massachusetts 02109.
(7) The ownership given for Greenlight Capital, L.L.C., David Einhorn and
Jeffrey H. Keswin is based on information contained in the Schedule 13D/A
dated November 4, 1999, filed with the Commission by Greenlight Capital,
L.L.C. in respect of its beneficial ownership of Triad Hospitals, Inc.
common stock. The address of Greenlight Capital, L.L.C. is 420 Lexington
Avenue, Suite 875, New York, New York 10170.
(8) The ownership given for Wellington Management Company, LLP is based on
information contained in the Schedule 13G/A dated February 11, 2000, filed
with the Commission by Wellington Management Company, LLP in respect of its
beneficial ownership of Triad Hospitals, Inc. common stock. The address of
Wellington Management Company, LLP is 75 State Street, Boston,
Massachusetts 02109. Wellington Management Company, LLP reported in its
Schedule 13G/A that of the securities as to which such Schedule was filed,
more than five percent were securities as to which Vanguard Windsor Fund is
the owner of record.
(9) Of the shares reported for Messrs. Shelton, Parsons, Marzocco, Holden, Fay,
Huston, Love, McAlister and Whitman, 276,828, 105,502, 42,601, 38,639,
35,474, 46,949, 21,250, 23,750 and 95,000 shares, respectively, represent
shares that are issuable by options that are exercisable within 60 days.
3
<PAGE>
1. ELECTION OF DIRECTORS
The Company's certificate of incorporation provides that the Board of
Directors is to be divided into three classes of directors, which are required
to be as nearly equal in number as possible. At each annual meeting of
stockholders, one class of directors is elected to a term of three years.
Directors for Class I are to be elected at this 2000 Annual Meeting for three-
year terms expiring in 2003, and as described below, an additional Class II
director will be added effective as of the 2000 Annual Meeting.
Pursuant to the Company's certificate of incorporation, the Board of
Directors at the last regular quarterly meeting increased the authorized number
of the Company's directors from eight to 10 members, effective as of the 2000
Annual Meeting, and designated one of the newly created directorships as Class
II, to have a term expiring at the 2001 annual meeting of stockholders and the
other newly created directorship as Class I, to have a term expiring at the
2003 annual meeting of stockholders. Effective as of May 22, 2000, Marvin
Runyon, a Class I director of the Company with a term expiring at the 2000
Annual Meeting, will not stand for reelection to such seat, and will instead
stand for election to the newly created directorship in Class II having the
term expiring at the 2001 annual meeting.
Dale V. Kesler, Donald B. Halverstadt, M.D., and Barbara A. Durand, R.N.
have been nominated by the Board of Directors for election as Class I directors
at the 2000 Annual Meeting, each to serve for a term of three years, until the
2003 Annual Meeting of Stockholders or until his or her successor is duly
elected and qualified. Marvin Runyon has been nominated by the Board of
Directors for election as a Class II director at the 2000 Annual Meeting to
serve until the 2001 annual meeting of stockholders or until his successor is
duly elected and qualified. Messrs. Kesler and Runyon have served on the Board
of Directors of the Company since the date of the Company's spin-off from
Columbia/HCA on May 11, 1999 (the "Spin-Off"). Dr. Halverstadt and Ms. Durand
have been nominated to fill the vacancies resulting from the increase in the
authorized number of directors and Mr. Runyon's decision to stand for election
as a Class II director as described above.
The Board of Directors recommends a vote "FOR" the election of these
nominees as directors.
Proxies in the enclosed form received from holders of common stock prior to
the 2000 Annual Meeting will be voted for the election of the four nominees
named above as directors of the Company unless stockholders indicate otherwise.
If any of the foregoing nominees is unable to serve for any reason (which event
is not anticipated), the shares represented by the enclosed proxy may be voted
for such other person or persons as may be determined by the holders of such
proxy unless stockholders indicate otherwise. Directors will be elected by the
affirmative vote of a plurality of the shares of common stock present in person
or represented by proxy and entitled to vote at the 2000 Annual Meeting. Thus,
those nominees who receive the four highest number of votes for their election
as directors will be elected, regardless of the number of shares that are not
voted for the election of such nominees. Shares with respect to which authority
to vote for any nominee or nominees is withheld will not be counted in the
total number of shares voted for such nominee or nominees.
Information concerning each of the nominees named for election as directors
along with information concerning the Class II and Class III directors, whose
terms of office will continue after the 2000 Annual Meeting, is set forth
below.
4
<PAGE>
NOMINEES FOR ELECTION
CLASS I--TERM WILL EXPIRE IN 2003
DALE V. KESLER Director since 1999 Age 61
Dale V. Kesler served as a partner at Arthur Andersen LLP until April 1996
and as Managing Partner of Arthur Andersen's Dallas/Fort Worth office from 1983
to 1994. Mr. Kesler is a director of CellStar Corporation, Elcor Corporation,
American Homestar Corporation, New Millenium Homes, Resource Services, Inc. and
Compass Banks--Dallas.
BARBARA A. DURAND, R.N. Age 62
Barbara A. Durand, R.N. has served as Professor and Dean of the Arizona
State University College of Nursing since 1993. Prior to such time, she was
Professor and Chairperson in the Department of Maternal-Nursing, Rush
University, Rush-Presbyterian-St. Luke's Medical Center.
DONALD B. HALVERSTADT, M.D. Age 65
Donald B. Halverstadt, M.D. has served as Chief, Pediatric Urology Service,
Children's Hospital of Oklahoma, University of Oklahoma Health Science Center,
since 1967. He is also the Chairman of the University Board of Regents. Dr.
Halverstadt is a member of the corporate board of trustees of the Presbyterian
Health Foundation and the board of directors of Lincoln National Bank.
CLASS II NOMINEE--TERM WILL EXPIRE IN 2001
MARVIN RUNYON Director since 1999 Age 75
Marvin Runyon served as the 70th Postmaster General of the United States
from 1992 through 1998. Mr. Runyon was Chairman of the Board of the Tennessee
Valley Authority from 1988 to 1992 and President and Chief Executive Officer of
Nissan Motor Manufacturing Corporation U.S.A. prior thereto. Mr. Runyon is a
Director of ProTeam.com and Stamps.com.
DIRECTORS CONTINUING IN OFFICE
CLASS II -- TERM EXPIRES IN 2001
JAMES D. SHELTON Director since 1999 Age 46
James D. Shelton is the Chairman of the Board, President and Chief Executive
Officer and a Director of Triad since May 11, 1999. From January 1, 1998,
through May 11, 1999, he served as the President of the Pacific Group of
Columbia/HCA Healthcare Corporation ("Columbia/HCA"). Prior to that time, Mr.
Shelton served as President of the Central Group of Columbia/HCA from June 1994
until January 1, 1998; Executive Vice President of the Central Division of
National Medical Enterprises, Inc. (presently called Tenet Healthcare
Corporation) from May 1993 to June 1994; and Senior Vice President of
Operations of National Medical Enterprises, Inc. prior thereto.
THOMAS F. FRIST III Director since 1999 Age 31
Thomas F. Frist III is the Co-founder of FS Partners, LLC, a private
investment firm formed in 1994. Prior to such time, he was assistant to a
principal at Rainwater, Inc., a private investment firm.
GALE SAYERS Director since 1999 Age 56
Gale Sayers is President and CEO of Sayers Computer Sources, a computer
resale firm, that he co-founded in 1984. Mr. Sayers manages Sayers and Sayers
Enterprises, a sport marketing and public relations firm.
5
<PAGE>
CLASS III -- TERM EXPIRES IN 2002
MICHAEL J. PARSONS Director since 1999 Age 44
Michael J. Parsons is an Executive Vice President and Chief Operating
Officer and a Director of Triad since May 11, 1999. From January 1, 1998,
through May 11, 1999, he served as the Chief Operating Officer of the Pacific
Group of Columbia/HCA. Prior to that time, Mr. Parsons served as Chief
Financial Officer of the Central Group of Columbia/HCA from July 1994 until
January 1, 1998; and Chief Financial Officer of the Central Group of National
Medical Enterprises, Inc. prior thereto.
THOMAS G. LOEFFLER, Esq. Director since 1999 Age 53
Thomas G. Loeffler, Esq. has served as a Partner at the law firm of Arter &
Hadden LLP since June 1993; he was an attorney and a consultant prior thereto.
Mr. Loeffler served as a member of the U.S. Congress from 1979 to 1987. Mr.
Loeffler is a Director of Billing Concepts Corp., and is Vice Chairman of the
Board of Regents of the University of Texas System.
UWE E. REINHARDT, Ph.D Director since 1999 Age 60
Uwe E. Reinhardt, Ph.D. is the James Madison Professor of Political Economy
and Professor of Economics and Public Affairs at Princeton University. Mr.
Reinhardt is a Trustee of Duke University Health Center, H&Q Healthcare
Investors and H&Q Life Sciences Investors, a Member of the Board of the Center
for Healthcare Strategies, Inc. and a Member of the External Advisory Panel for
Health, Nutrition and Population, The World Bank.
MEETINGS AND COMMITTEES OF THE BOARD OF DIRECTORS
The Board of Directors held four meetings in 1999. Each director attended at
least seventy-five percent of the aggregate of (a) all meetings of the Board of
Directors and (b) all meetings of the committees of the Board of Directors on
which such director served.
The Board of Directors has a number of standing committees, including an
Executive Committee, an Audit and Compliance Committee, a Quality Committee and
a Compensation Committee. The Board of Directors does not have a standing
nominating committee, but rather acts as a committee of the whole to screen
candidates to be nominated for election thereto by the stockholders or chosen
to fill newly created directorships or vacancies on the Company's Board of
Directors.
The Executive Committee may exercise certain powers of the Board of
Directors regarding the management and direction of the business and affairs of
the Company when the Board of Directors is not in session. All action taken by
the Executive Committee is reported to and reviewed by the Board of Directors.
The members of the Executive Committee are Mr. Loeffler, Mr. Kesler and Mr.
Shelton, with Mr. Shelton serving as Chair. The Executive Committee held no
meetings in 1999.
The Audit and Compliance Committee of the Board of Directors reviews and
makes reports and recommendations to the Board of Directors with respect to the
selection of the independent auditors of the Company and its subsidiaries, the
arrangements for and the scope of the audits to be performed by them and the
internal audit activities, accounting procedures and controls of the Company,
and reviews the annual consolidated financial statements of the Company. The
Committee also monitors adherence to the Company's regulatory compliance
program. The members of the Audit and Compliance Committee are Dr. Reinhardt,
Mr. Kesler and Mr. Runyon, with Mr. Kesler serving as Chair. The Audit and
Compliance Committee held four meetings in 1999.
The Quality Committee of the Board of Directors is responsible for reviewing
the quality of services provided to patients at various health care facilities
operated by the Company's subsidiaries. The members of the Quality Committee
are Mr. Parsons and Dr. Randy Prust, president of the Company's National
Physician Leadership Group, in an ex officio capacity.
6
<PAGE>
The Compensation Committee of the Board of Directors is responsible for
approving compensation arrangements for executive management of the Company,
reviewing compensation plans relating to officers, grants of options and other
benefits under the Company's employee benefit plans and reviewing generally the
Company's employee compensation policy. The members of the Compensation
Committee are Mr. Sayers, Mr. Frist and Mr. Loeffler, with Mr. Loeffler serving
as Chair. The Compensation Committee held three meetings in 1999.
COMPENSATION OF DIRECTORS
The annual retainer for outside directors who are neither officers nor
employees of the Company is $18,000 and the Board meeting fee is $1,500 per
meeting. Committee members receive a fee of $500 per meeting payable only for
attendance at committee meetings not held in conjunction with a meeting of the
Board of Directors. Directors also are reimbursed for expenses incurred
relating to attendance at meetings. Under the outside directors stock and
incentive compensation plan, each non-employee director may elect to receive,
in lieu of all or any portion, in multiples of 25%, of his annual retainer,
deferred stock units, the payout of which, at the election of the director, may
be deferred for five years or until the end of such director's term of office.
The payment of deferred stock units will be made through the issuance of a
stock certificate for a number of shares equal to the number of deferred stock
units.
The plan further provides that each non-employee director will receive a
one-time grant of an option, as of a date to be selected by the Board, to
acquire shares of Triad common stock, exercisable at the fair market value of
Triad common stock on the date of grant, for a number of shares to be
determined by the Board. Each person who is a non-employee director on the day
of the annual meeting of Triad's stockholders will be granted on a date to be
selected by the Board, an option to acquire shares of Triad common stock,
exercisable at the fair market value of Triad common stock on the date of
grant, for a number of shares to be determined by the Board. The one-time
options and the annual options will each become exercisable as to one-quarter
of the shares covered by the option on each of the first four anniversaries of
the date of grant. Upon the occurrence of a change of control of Triad, each
outstanding option shall become fully and immediately exercisable.
The plan further provides that non-employee directors may receive
discretionary option grants.
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
During fiscal 1999, members of the Compensation Committee were Gale Sayers,
Thomas F. Frist III and Thomas G. Loeffler. None of Messrs. Sayers, Frist or
Loeffler are current or former officers or employees of the Company.
NAMED EXECUTIVE OFFICERS WHO ARE NOT DIRECTORS
BURKE W. WHITMAN, age 44, has served as Executive Vice President, Chief
Financial Officer and Treasurer of the Company since May 11, 1999. From
February 1, 1999, through May 11, 1999, he served as Chief Financial Officer of
the Pacific Group of Columbia/HCA. From May 1994 until January 31, 1999, he
served as President, Chief Financial Officer, Director and Co-founder of
Deerfield Healthcare Corporation. Prior to such time, Mr. Whitman served as
Vice President, Development and Finance of Almost Family, Inc., a wholly-owned
subsidiary of Caretenders HealthCorp.
DONALD P. FAY, age 56, has served as an Executive Vice President, Secretary
and the General Counsel of the Company since May 11, 1999. From January 1,
1998, through May 11, 1999, he served as Senior Vice President of the Pacific
Group of Columbia/HCA. Prior to that time, Mr. Fay served as Vice President--
Legal of Columbia/HCA from February 1994 through December 1997, and Senior
Counsel of Columbia/HCA prior thereto.
7
<PAGE>
CHRISTOPHER A. HOLDEN, age 35, has served as a Senior Vice President of the
Company since May 11, 1999. From January 1, 1998, through May 11, 1999, he
served as President--West Division of the Pacific Group of Columbia/HCA. Prior
to such time, Mr. Holden was President of the West Texas Division of the
Central Group of Columbia/HCA from September 1997 until January 1, 1998; Vice
President of Administration for the Central Group of Columbia/HCA from August
1994 until September 1997; and Assistant Vice President--Administration of the
Central Group of National Medical Enterprises, Inc. prior thereto.
NICHOLAS J. MARZOCCO, age 45, has served as a Senior Vice President of the
Company since May 11, 1999. From January 1, 1998, through May 11, 1999, he has
served as President--East Division of the Pacific Group of Columbia/HCA. Prior
to that time, Mr. Marzocco served as Chief Operating Officer of the Louisiana
Division of Columbia/HCA from September 1996 until January 1, 1998; and Chief
Executive Officer of North Shore Regional Medical Center, a 310-bed hospital
owned by National Medical Enterprises, Inc. and located in Slidell, Louisiana,
prior thereto.
G. WAYNE MCALISTER, age 54 has served as a Senior Vice President of the
Company since May 11, 1999. From March 15, 1999, through May 11, 1999, he
served as President--Central Division of the Pacific Group of Columbia/HCA.
Prior to such time Mr. McAlister was an independent senior hospital management
consultant from June 1997 until March 15, 1999; Regional Vice President of
Paracelsus Healthcare Corporation from June 1995 until May 1997; Vice
President, Operations, of Tenet Healthcare Corporation from August 1993 until
May 1995; and President/Chief Operating Officer and Vice President of
Operations of Healthcare International from February 1988 until November 1992.
W. STEPHEN LOVE, age 48, has served as a Senior Vice President of Finance
and the Controller of the Company since May 11, 1999. From March 1, 1999,
through May 11, 1999, he served as Senior Vice President of Finance/Controller
of the Pacific Group of Columbia/HCA. Prior to that time he served as Senior
Vice President/Corporate Chief Financial Officer-Operations of Charter
Behavioral Health Systems, L.L.C. (formerly Charter Medical System) from
December 1997 until March 1, 1999; Senior Vice President/Corporate Chief
Financial Officer of Charter Behavioral Health Systems, L.L.C. from June 1997
until December 1997; and Vice President, Financial and Hospital Operations of
Charter Medical System prior thereto.
WILLIAM R. HUSTON, age 45, has served as a Senior Vice President of Finance
of the Company since May 11, 1999. From January 1999, through May 11, 1999, he
served as Senior Vice President of Finance of the Pacific Group of
Columbia/HCA. Prior to that time he served as Division Chief Financial Officer
of various divisions of the Central Group of Columbia/HCA from April 1995 to
December 1998; and Division Chief Financial Officer of Tenet Healthcare
Corporation prior thereto.
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934 requires our executive
officers and directors, and persons who own more than ten percent of the
outstanding common stock of the Company, to file reports of ownership and
changes in ownership with the Securities and Exchange Commission and to provide
us with copies of these reports. To the Company's knowledge, based solely on
our review of the copies of such reports furnished to the Company and
representations that no other reports were required, all Section 16(a) filing
requirements applicable to all of our executive officers, directors and greater
than ten-percent stockholders were complied with during fiscal 1999, except one
filing by Gale Sayers, a director of the Company, who inadvertently filed late
due to an administrative oversight.
8
<PAGE>
EXECUTIVE COMPENSATION
The information under this heading relates to the chief executive officer
and the four other most highly compensated executive officers of the Company
serving as executive officers at the end of 1999, and reflects compensation
paid by the Company or, prior to the Spin-Off on May 11, 1999, by Columbia/HCA.
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
Annual Compensation Long-Term Compensation
----------------------------------- ------------------------------------
Other Restricted Securities All
annual stock underlying other
Name and Principal Salary Bonus Compensation awards options/SARS compensation
Position Year ($) (1) ($) (2) (3) ($) (4) (#) (5) (6)
- ------------------ ---- -------- -------- ------------ ---------- ------------ ------------
<S> <C> <C> <C> <C> <C> <C> <C>
James D. Shelton........ 1999 $614,528 $245,884 $ -- $ -- 643,128 $5,448
Chairman, President and 1998 $529,125 $ -- $ -- $124,490 -- $9,448
Chief Executive Officer 1997 $415,000 $ -- $ -- $221,400 350,000 $7,629
Burke W. Whitman........ 1999 $293,754 $ 78,605 $ -- $ -- 260,000 $ 299
Executive Vice
President, Chief
Financial Officer and
Treasurer (7)
Michael J. Parsons...... 1999 $374,039 $129,976 $ -- $ -- 296,482 $2,505
Executive Vice Presi-
dent and 1998 $309,375 $ -- $ -- $ 37,493 -- $7,561
Chief Operating Officer 1997 $225,000 $ 56,250 $ -- $ 75,000 135,000 $7,629
Nicholas J. Marzocco.... 1999 $303,026 $ 87,281 $ -- $ -- 113,431 $4,846
Senior Vice President 1998 $271,688 $ -- $34,488 $ 51,745 -- $7,224
1997 $207,000 $ 77,625 $31,158 $ 34,510 64,000 $7,004
Christopher A. Holden... 1999 $281,522 $ 74,198 $ -- $ -- 99,409 $8,521
Senior Vice President 1998 $243,750 $ -- $26,594 $ 64,997 -- $7,399
1997 $195,000 $ 42,840 $28,950 $ -- 60,000 $6,373
</TABLE>
- --------
(1) 1998 salary amounts do not include the value of restricted stock awards
granted in lieu of a portion of annual salary.
(2) Reflects bonus earned during the fiscal year. In some instances, all or a
portion of the bonus was paid during the following fiscal year. Each of the
executive officers identified in the table, except for Mr. Holden, had the
option to take all or part of their 1998 or 1997 bonus in shares of
Columbia/HCA restricted stock at a 25% discount from the fair market value
at the time of grant, which is reflected in the Restricted Stock Awards
column. Columbia/HCA's cash bonus program was discontinued in August 1997.
(3) Perquisites and other personal benefits did not exceed the lesser of either
$50,000 or 10% of the total of annual salary and bonus for any executive
officer identified in the table. Other compensation consists principally of
relocation expenses.
(4) 1998 amounts represent the average of the closing prices of Columbia/HCA
shares issued pursuant to Columbia/HCA's amended and restated 1995
management stock purchase plan in lieu of a portion of annual salary on
trading days during the deferral period. 1997 amounts represent the average
of the closing price on the five trading days prior to the grant date of
shares of Columbia/HCA shares granted pursuant to Columbia/HCA's amended
and restated 1995 management stock purchase plan in lieu of all or a
portion of a cash bonus. As of January 1, 1999, Messrs. Shelton, Parsons,
Marzocco and Holden held an aggregate of 21,172, 6,971, 3,136 and 2,453
shares of restricted stock, respectively. Pursuant to Commission rules,
after deducting the consideration paid therefor, the shares held by Messrs.
Marzocco and Holden had a net pre-tax value of $12,933 and $11,965,
respectively, and the shares held by Messrs. Shelton and Parsons were
without value. Dividends will be payable on shares of restricted stock if
and to the extent paid on Columbia/HCA's common stock generally, regardless
of whether or not the shares are vested.
9
<PAGE>
(5) Options granted in 1997 are to acquire shares of Columbia/HCA common stock.
Columbia/HCA granted options at two separate times in 1997. The 1997
regular grant was issued in February 1997. A special grant was issued in
November 1997 to help ensure the retention and motivation of key
executives, including Messrs. Shelton, Parsons, Marzocco and Holden, at the
time Columbia/HCA was reorganizing. On average, the size of the November
1997 grant is two times a competitive median long-term grant for a two-year
period (1998-99).
(6) Consists of contributions to the savings and investment plan, money
purchase plan and stock bonus plan.
(7) On May 11, 1999, the Company named Burke W. Whitman as Executive Vice
President, Chief Financial Officer and Treasurer.
10
<PAGE>
OPTION/SAR GRANTS IN LAST FISCAL YEAR
<TABLE>
<CAPTION>
Potential
Realizable Value At
Assumed Annual
Rates of Stock
Price Appreciation
for Securities
Option Term
-------------------
Percent of
Total
Number of Options/SARs Exercise
Securities Granted to or Base
Underlying Employees in Price Expiration
Name SARS/Options(#)(1) Fiscal Year ($/sh)(2)(3) Date 5%($) 10%
- ---- ------------------ ------------ ------------ ---------- --------- ---------
<S> <C> <C> <C> <C> <C> <C>
James D. Shelton........ 300,000 8.76% 9.375 5/26/09 1,768,766 4,482,401
335,500 9.80% 11.5 6/9/09 2,426,433 6,149,057
1,776 0.06% 12.4384 6/17/04 5,211 21,384
2,367 0.06% 12.6354 2/9/05 6,480 28,032
2,170 0.06% 17.7919 2/8/06 -- 14,510
1,315 0.04% 18.835 2/3/07 -- 7,421
Michael J. Parsons...... 60,000 1.75% 9.375 5/26/09 353,753 896,480
233,300 6.81% 11.5 6/9/09 1,687,293 4,275,931
888 0.03% 12.5173 7/18/04 2,535 10,620
888 0.03% 12.6354 2/9/05 2,430 10,518
946 0.03% 17.7919 2/8/06 -- 6,326
460 0.01% 18.835 2/3/07 -- 2,596
Nicholas J. Marzocco.... 30,000 0.88% 9.4375 5/27/09 178,056 451,228
83,050 2.42% 11.5 6/9/09 600,642 1,522,144
197 0.01% 17.91 9/30/06 -- 1,294
184 0.01% 18.835 2/3/07 -- 1,038
Burke W. Whitman........ 120,000 3.50% 9.375 5/26/09 707,506 1,792,960
140,000 4.09% 11.5 6/9/09 1,012,520 2,565,925
Christopher A. Holden... 30,000 0.88% 9.4375 5/27/09 178,056 451,228
68,784 2.01% 11.5 6/9/09 497,466 1,260,676
180 0.01% 12.6354 2/9/05 492 2,133
314 0.01% 17.7919 2/8/06 -- 2,100
131 0.00% 18.835 2/3/07 -- 739
</TABLE>
- --------
(1) Options to acquire Triad common stock.
(2) The option exercise price may be paid in shares of Triad common stock owned
by the executive officer, in cash, or a combination thereof.
(3) The ten-year options become exercisable with respect to 25% of the shares
covered thereby on the first, second, third and fourth anniversary dates
following the date of grant. The exercise price was equal to the fair
market value of the Triad common stock on the date of the grant. All
options listed in the table with expiration dates prior to the year 2009
reflect options granted at the time of the Spin-Off with respect to
previously vested Columbia/HCA options that retained the pre-Spin-Off
intrinsic value and the pre-Spin-Off ratio of exercise prices to underlying
market value of the related common stock.
(4) The potential realizable value portion of the foregoing table illustrates
value that might be realized upon exercise of the options immediately prior
to the expiration of their term, assuming the specified compounded rates of
appreciation on the Triad common stock over the term of the options. These
amounts do not take into account provisions of the options relating to
termination of the option following termination of employment, non-
transferability or vesting over periods of up to four years.
11
<PAGE>
AGGREGATED OPTION/SAR EXERCISES IN LAST FISCAL YEAR AND FY-END
OPTION/SAR VALUES
<TABLE>
<CAPTION>
Number of Securities Value of Unexercised
Underlying Unexercised In-the-Money
Options/SARs at Fiscal Options/SARs at Fiscal
Year End(#) Year-End($)(1)
------------------------- -------------------------
Exercisable Unexercisable Exercisable Unexercisable
----------- ------------- ----------- -------------
<S> <C> <C> <C> <C>
James D. Shelton............ 207,728 435,400 1,054,775 1,897,075
Michael J. Parsons.......... 51,842 244,640 244,670 950,570
Nicholas J. Marzocco........ 23,991 89,440 116,524 355,158
Burke W. Whitman............ 60,000 200,000 345,000 852,500
Christopher A. Holden....... 23,322 76,087 113,662 306,753
</TABLE>
- --------
(1) The closing price for the Triad common stock, as reported by the NASDAQ, on
December 31, 1999 was $15.125 per share. Value is calculated on the basis
of the difference between the option exercise price and $15.125 per share,
multiplied by the number of shares of Triad common stock underlying the
option.
EMPLOYMENT CONTRACTS, TERMINATION OF EMPLOYMENT ARRANGEMENTS
AND CHANGE IN CONTROL ARRANGEMENTS
None of the executive officers of the Company is subject to any employment
contract. All employees of the Company participate in the Company's severance
policy, under which, in certain circumstances, an employee whose employment
with the Company is involuntarily terminated may receive as a severance benefit
up to 52 weeks of salary.
CERTAIN TRANSACTIONS
Triad made loans to certain executive officers in connection with such
officers' initial purchases of Triad common stock under the Triad executive
stock purchase plan, the balances are as follows: Mr. Shelton, $3,746,000; Mr.
Parsons, $749,200; Mr. Marzocco, $377,100; Mr. Holden, $377,100; Mr. Fay,
$377,100; Mr. Huston, $377,100; Mr. Love, $374,600; Mr. McAlister, $282,825;
and Mr. Whitman, $1,498,400.
COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION
Decisions on compensation for the Company's executives are made by the
Compensation Committee of the Board of Directors. Each member of the
Compensation Committee is a non-employee director. No member of the
Compensation Committee is a current or former employee or officer of the
Company or any of its affiliates. The Compensation Committee is responsible for
approving compensation arrangements for executive management of the Company,
reviewing compensation plans relating to officers, grants of options and other
benefits under the Company's employee benefit plans and reviewing generally the
Company's employee compensation policy. Pursuant to certain rules of the
Securities and Exchange Commission designed to enhance disclosure of corporate
policies toward executive compensation, set forth below is a report submitted
by the Compensation Committee.
Compensation Philosophy and Policies of Executive Officers
The Company believes that the most effective executive compensation program
aligns the interests of stockholders and executives. The Company's primary
objective is to provide quality health care services while
12
<PAGE>
enhancing the financial performance of the Company and long-term stockholder
value. At the Company there is a strong link between strategic business goals
and compensation and benefit goals. One of the primary reasons for the
Company's Spin-Off from Columbia/HCA was the need to more closely tie
compensation incentives for the Company's employees to the performance of the
Company. As an independent public company, the Company is able to provide
equity-based compensation and incentives to enable it to retain and recruit
senior management and motivate employees throughout the organization.
Annual Compensation
Cash Compensation
The base salaries of the named executive officers are listed in the Summary
Compensation Table found under "Executive Compensation" in this Proxy
Statement. These salaries and the salaries of other executive officers are
evaluated annually. The Board of Directors and the Compensation Committee
ratified the Company's executive compensation salary structure for 1999 as
designated by the Columbia/HCA Compensation Committee. In determining
appropriate salary levels and salary increases, several factors are considered,
including individual performance, experience, level of responsibility and
external pay practices.
In 1999 the Company adopted an Annual Incentive Plan to provide for the
payment of annual cash bonuses following the close of each plan year to
eligible employees based upon the achievement of objective performance
criteria. Annual incentive award opportunities at the Company are designed to
focus management attention on key operational goals deemed important for the
upcoming fiscal year, and to support the Company's strategic goal for
consistent growth by highlighting corporate and business unit earnings as the
main performance measure affecting incentive bonus payments. Bonus awards are
contingent upon meeting or exceeding certain performance goals such as, for
corporate office employees, attainment of the Company's budgeted earnings
before interest, taxes, depreciation and amortization, and for hospital
employees, additional attainment of budgeted facility cash flow and target
patient and physician satisfaction goals for such plan year. The Compensation
Committee determines the participants and sets the target bonus levels prior to
the beginning of each year. The maximum award payable to any individual for any
plan year is $750,000.
Equity-Based Compensation
Equity based compensation may be provided in the form of stock options,
performance awards and restricted shares of common stock.
Stock option grants provide an incentive that focuses the executive's
attention on managing the business of our company from the perspective of an
owner with an equity stake in the business and helps ensure that operating
decisions are based on long-term results that benefit the business and
ultimately our stockholders. Specifically, the option grants to executive
officers provide the right to purchase shares of common stock at the fair
market value on the date of the grant. Usually, each stock option becomes
vested and exercisable only over a period of time, generally one to five years.
The number of shares covered by each grant reflects the executive's level of
responsibility and past and anticipated contributions.
Triad has granted stock options to certain of its executive and other
employees pursuant to its 1999 Long-Term Incentive Plan, which is discussed
more fully below under "Approval of 1999 Long-Term Incentive Plan."
Approximately 4,746,000 options have been granted to Triad employees pursuant
to this plan. The plan also provides for the granting of restricted stock
awards and various other performance awards; however, Triad has not granted any
of such other awards under the plan.
Finally, certain officers may elect to receive up to a specified percentage
of their base salary (25% for senior vice presidents and above, and 10% for
corporate vice presidents and hospital chief executive officers) in restricted
shares of common stock. These restricted shares are granted at a 25% discount
from the fair market value of the common stock on the date of the grant. The
restricted period is generally three years from the date
13
<PAGE>
of grant. With certain exceptions, if employment is terminated during the
restricted period, the employee receives a cash payment equal to the lesser of
(a) the then-current fair market value of the restricted shares or (b) the
aggregate salary foregone by the employee as a condition to receiving the
restricted shares. Any additional value is forfeited.
Chief Executive Officer Compensation
Mr. Shelton does not have an employment contract. During 1999 Mr. Shelton's
salary totaled $614,528. As Chief Executive Officer, Mr. Shelton's compensation
during 1999 consisted of the same components as for other executive officers,
namely base salary, Annual Incentive Plan bonus, and stock options. In
establishing Mr. Shelton's compensation, the Committee applied the principles
outlined above in the same manner as they were applied to other executives. The
Committee believes that the base salary paid to Mr. Shelton in 1999 was
justified in light of his significant critical contributions to the day-to-day
business operations of the Company during its initial existence as an
independent publicly traded company, including improvement in the operations of
the Company's "core" healthcare facilities, and the disposition of nine
hospitals that for various reasons were incompatible with the Company's long-
term business strategies.
Section 162(m) of the Internal Revenue Code of 1986
The Revenue Reconciliation Act of 1993 added Section 162(m) to the Internal
Revenue Code of 1986, as amended. Section 162(m), which became effective for
tax years beginning January 1, 1994, disallows a deduction to the Company for
any compensation paid to a "covered employee" in excess of $1 million per year,
subject to certain exceptions. In general, "covered employees" include the
chief executive officer and the four other most highly compensated executive
officers of the Company who are in the employ of the Company and are officers
at the end of the tax year. Among other exceptions, the deduction limit does
not apply to compensation that meets the specified requirements for
"performance-based compensation." Those requirements include the establishment
of objective performance goals by a committee of the Board of Directors
composed solely of two or more outside directors, stockholder approval of the
material terms of the performance goals under which the compensation is to be
paid prior to payment of such compensation, and certification by the committee
that the performance goals have been achieved. While the Compensation Committee
believes that the Company should seek to obtain maximum deductibility of
compensation paid to executive officers, the Compensation Committee also
believes that the interests of the Company and its stockholders are best served
by assuring that appropriate compensation arrangements are established to
retain and motivate executive officers.
Because the Company establishes individual compensation based primarily upon
company performance and competitive considerations, executive officer
compensation may exceed $1 million in a given year. No executive officer whose
compensation is subject to this limit on deductibility was considered to
receive, for 1999 federal income tax purposes, base salary and other non
performance-based compensation in excess of $1 million.
The Compensation Committee:
Thomas G. Loeffler, Esq., Chairman
Thomas F. Frist III
Gale Sayers
14
<PAGE>
PERFORMANCE GRAPH
The following graph compares at the end of 1999 the cumulative total
stockholder return on the Company's common stock, the cumulative total return
of the companies on the Standard & Poor's Midcap 400 Index (the "S&P Midcap
400") and the cumulative total return on the Standard and Poor's Hospital
Management Index (the "Hospital Index") over the same period.
[PERFORMANCE GRAPH]
<TABLE>
<CAPTION>
May 11, December
1999 1999
------- --------
<S> <C> <C>
Triad.................................................... 100 144.05
Hospital Index........................................... 100 116.69
S&P MidCap 400........................................... 100 113.58
</TABLE>
The foregoing performance graph assumes the investment of $100 on May 11,
1999 (the first day of regular trading of the common stock of the Company on
the NASDAQ), and the reinvestment of any cash dividend on the ex-dividend date
in respect of such dividend.
2. RATIFICATION OF SELECTION OF INDEPENDENT AUDITORS
The Board of Directors has selected PricewaterhouseCoopers LLP, independent
certified public accountants, as independent auditors for the Company for the
year 2000. A resolution will be submitted to stockholders at the meeting for
ratification of such selection. Although ratification by stockholders is not a
15
<PAGE>
prerequisite to the ability of the Board of Directors to select
PricewaterhouseCoopers LLP as the Company's independent auditors, the Company
believes such ratification to be desirable. If the stockholders do not ratify
the selection of PricewaterhouseCoopers LLP, the selection of independent
auditors will be reconsidered by the Board of Directors; however, the Board of
Directors may select PricewaterhouseCoopers LLP notwithstanding the failure of
the stockholders to ratify its selection.
The Board of Directors recommends a vote "FOR" this resolution. Proxies
solicited by the Board of Directors will be so voted unless stockholders
specify a contrary vote. The resolution may be adopted by a majority of the
votes cast with respect thereto.
PricewaterhouseCoopers LLP have been the Company's independent auditors
since November 22, 1999.
It is expected that a representative of PricewaterhouseCoopers LLP will be
present at the meeting, will have an opportunity to make a statement if he or
she desires to do so, and will be available to respond to appropriate
questions.
3. APPROVAL OF 1999 LONG-TERM INCENTIVE PLAN
Set forth below is a description of the Triad Hospitals, Inc. 1999 Long-Term
Incentive Plan, which was approved by the Triad Board of Directors. The plan
provides for the grant of stock options, including both incentive stock options
and nonqualified stock options, as well as stock appreciation rights,
restricted stock, performance awards, phantom stock, and dividend equivalents,
as described below. The purpose of the plan is to promote the interests of
Triad and its shareholders by strengthening Triad's ability to attract,
motivate and retain personnel upon whose judgement, initiative, and efforts the
financial success and growth of Triad's business largely depend. The plan is
designed to allow for the grant of certain types of awards that conform to the
requirements for tax deductible "performance-based" compensation under section
162(m) of the Code. The purpose of submitting the plan to the shareholders at
the annual meeting is to allow awards granted under the plan to Triad's
executive officers to qualify as "performance-based" compensation under section
162(m) of the Code. This will allow Triad to preserve the tax-deductibility of
such awards without regard to the limitations of section 162(m) of the Code. A
brief description of the material features of the plan is set forth below, but
is qualified by reference to the full text of the plan attached as Exhibit A to
this Proxy Statement.
Description of the Plan
Administration.
The plan is administered by the compensation committee of the Triad Board.
The compensation committee is constituted to comply with the "outside director"
requirements under section 162(m) of the Code and the "non-employee director"
requirements under Rule 16b-3 of the Securities Exchange Act of 1934.
Generally, the compensation committee has the authority to determine the
persons to whom awards are granted, the types of awards to be granted, the time
at which awards will be granted, the number of shares, units or other rights
subject to each award, the exercise, base or purchase price of an award (if
any), the time or times at which the award will become vested, exercisable or
payable, the performance criteria, performance goals and other conditions of an
award, and the duration of the award.
Eligibility. All employees of Triad and its subsidiaries and, in the case of
awards other than incentive stock options, any consultant or independent
contractor providing services to Triad or a subsidiary, are eligible to be
granted awards under the plan, as selected from time to time by the
compensation committee.
Reservation of Shares. Under the plan, 5,350,000 shares of Triad common
stock have been reserved for issuance. The shares of Triad common stock to be
issued under the plan will be made available from authorized but unissued
shares of Triad common stock or issued shares that have been reacquired by
Triad. If any shares of Triad common stock that are the subject of an award are
not issued and cease to be issuable for any reason,
16
<PAGE>
such shares will no longer be charged against such maximum share limitation and
may again be made subject to awards. In the event of certain corporate
reorganizations, recapitalizations, or other specified corporate transactions
affecting Triad or the Triad common stock, proportionate adjustments may be
made to the number of shares available for grant, as well as the other maximum
share limitations, under the plan, and number of shares and prices under
outstanding awards.
Types of Awards. The plan authorizes the grant of the following types of
awards:
. Nonqualified and Incentive Stock Options. The maximum number of shares
that may be covered under options granted to any one participant in any
calendar year is 700,000 shares. The exercise price of an option will be
determined by the compensation committee, provided that the exercise
price per share of an option may not be less than the fair market value
of a share of Triad common stock on the date of grant. The value of
Triad common stock (determined at the time of grant) that may be subject
to incentive stock options that become exercisable by any one employee
in any one year is limited to $100,000. The maximum term of stock
options granted under the plan is ten years from the date of grant. The
compensation committee is to determine the extent to which an option
will become and/or remain exercisable in the event of termination of
employment or service of a participant under various circumstances,
including retirement, death or disability, subject to certain
limitations for incentive stock options. Subject to certain terms and
conditions, an option may be exercised in whole or in part at any time
during the term thereof by written notice to Triad, together with
payment of the aggregate exercise price of the option. In addition to
the exercise price, the participant must pay Triad in cash or, at the
compensation committee's discretion in Triad common stock, the full
amount of all applicable income tax and employment tax amounts required
to be withheld in connection with the exercise of the option.
. Stock Appreciation Rights. A stock appreciation right may be granted
either in tandem with an option or without a related option. A stock
appreciation right entitles the holder, upon exercise, to receive a
payment based on the excess of the fair market value of a share of Triad
common stock on the date of exercise over the base price of the stock
appreciation right (which may not be less than the fair market value of
a share of Triad common stock on the date of grant), multiplied by the
number of shares as to which such stock appreciation right is being
exercised. The maximum term of a stock appreciation right will be ten
years from the date of grant. No more than 700,000 shares of Triad
common stock may be subject to stock appreciation rights granted to any
one participant during any calendar year. Stock appreciation rights are
payable, in the discretion of the compensation committee, in cash, in
shares of Triad common stock, or in a combination of cash and shares of
Triad common stock.
. Performance Awards. Performance awards are units denominated on the date
of grant either in shares of Triad common stock ("performance shares")
or in specified dollar amounts ("performance units"). The compensation
committee may grant performance awards that are intended to qualify as
performance-based compensation under 162(m) of the Code, as well as
performance awards that are not so intended to qualify. Performance
awards are payable upon the achievement of performance criteria
established by the compensation committee at the beginning of the
applicable performance period. At the time of grant, the compensation
committee establishes the number of units, the duration of the
performance period or periods, the applicable performance criteria, and,
in the case of performance units, the target unit value or range of unit
values for the performance awards. At the end of the performance period,
the compensation committee determines the payment to be made, based on
the extent to which the performance goals have been achieved.
Performance awards are payable, in the discretion of the compensation
committee, in cash, in shares of Triad common stock, or in a combination
of cash and shares of Triad common stock. The maximum amount of
compensation that may be payable to a participant during any one
calendar year with respect to a performance unit shall be $4.2 million.
The maximum number of performance shares granted to any one participant
during any calendar year shall be 280,000 performance shares.
17
<PAGE>
The performance criteria upon which the payment or vesting of a performance
award that is intended to qualify as performance-based compensation under
162(m) of the Code is limited to one or more of the following business
measures, which may be applied with respect to Triad, any subsidiary or any
business unit, and which may be measured on an absolute or relative to peer-
group basis: (i) total shareholder return, (ii) stock price increase, (iii)
return on equity, (iv) return on capital, (v) earnings per share, (vi) EBIT
(earnings before interest and taxes), and (vii) cash flow (including operating
cash flow, free cash flow, discounted cash flow return on investment, and cash
flow in excess of costs of capital). In the case of performance awards that are
not intended to qualify as performance-based compensation under 162(m) of the
Code, the compensation committee will designate performance criteria from among
the foregoing or from other business criteria that it determines appropriate.
. Phantom Stock. An award of phantom stock gives the participant the right
to receive payment at the end of a fixed vesting period based on the
value of a share of Triad common stock at the time of vesting. Phantom
stock units are subject to such restrictions and conditions to payment
as the compensation committee determines are appropriate. An award of
phantom stock may be granted, at the discretion of the compensation
committee, together with an award of dividend equivalent rights for the
same number of shares covered thereby. Phantom stock awards are payable,
in the discretion of the compensation committee, in cash, in shares of
Triad common stock having an equivalent fair market value on the
applicable vesting dates, or in a combination thereof.
. Restricted Stock Awards. An award of restricted stock represents shares
of Triad common stock that are issued subject to such restrictions on
transfer and incidents of ownership, and such forfeiture conditions, as
the compensation committee deems appropriate. The compensation committee
may grant an award of restricted stock that is intended to qualify as
performance-based compensation under 162(m) of the Code. The
restrictions imposed upon an award of restricted stock will lapse in
accordance with the vesting requirements specified by the compensation
committee in the award agreement. Such vesting requirements may be based
on the continued employment of the participant for a specified time
period or on the attainment of specified business goals or performance
criteria established by the compensation committee which, in the case of
awards intended to qualify under section 162(m) of the Code, will be
based on the performance criteria described above under the heading
"Performance Awards." The compensation committee may, in connection with
an award of restricted stock, require the payment of a specified
purchase price. Subject to the transfer restrictions and forfeiture
restrictions relating to the restricted stock award, the participant
will have the rights of a stockholder of Triad, including all voting and
dividend rights, during the restriction period, unless the compensation
committee determines otherwise at the time of the grant. The maximum
number of shares of Triad common stock that may be subject to a
restricted stock award granted to a participant during any one calendar
year shall be 280,000 shares.
. Dividend Equivalents. Dividend equivalent awards entitle the holder to a
right to receive cash payments determined by reference to dividends
declared on the Triad common stock during the term of the award, which
shall not exceed ten years from the date of grant. Dividend equivalent
awards may be granted on a stand-alone basis or in tandem with other
awards under the plan. Dividend equivalent awards are payable in cash or
in shares of Triad common stock, as determined by the compensation
committee.
Transferability. Awards under the plan are not transferable, except by will
or the laws of descent and distribution or for certain transfers to a
participant's family members, charitable institutions or such other persons or
entities approved by the compensation committee, subject to such limitations as
described in the plan.
Change-In-Control. The compensation committee may, in an award agreement,
provide for the effect of a change-in-control (as defined in the plan) on the
award. Such provisions may include the acceleration of an award's vesting or
extension of the time for exercise, the elimination or modification of
performance or other conditions, the cash settlement of an award or other
adjustments that the compensation committee considers appropriate.
18
<PAGE>
Federal Income Tax Consequences
Stock Options. An optionee will not generally recognize taxable income upon
the grant of a nonqualified stock option to purchase shares of Triad common
stock. Upon exercise of the option, the optionee will generally recognize
ordinary income for federal income tax purposes equal to the excess of the fair
market value for the shares over the exercise price. An optionee who sells any
of the shares will recognize capital gain or loss measured by the difference
between the tax basis of the shares and the amount realized on the sale. The
tax basis of the shares in the hands of the optionee will equal the exercise
price paid for the shares plus the amount of ordinary compensation income the
optionee recognizes upon exercise of the option, and the holding period for the
shares for capital gains purposes will commence on the day the option is
exercised. Triad will be entitled to a federal income tax deduction equal to
the amount of ordinary compensation income recognized by the optionee. The
deduction will be allowed at the same time the optionee recognizes the income.
An optionee will not generally recognize income upon the grant of an
incentive stock option to purchase shares of Triad common stock and will not
generally recognize income upon exercise of the option, provided the optionee
is an employee of Triad or a subsidiary at all times from the date of grant
until three months prior to exercise. However, the amount by which the fair
market value of the shares on the date of exercise exceeds the exercise price
will be includable for purposes of determining any alternative minimum taxable
income of an optionee. Where an optionee who has exercised an incentive stock
option sells the shares acquired upon exercise more than two years after the
grant date and more than one year after exercise, capital gain or loss will be
recognized equal to the difference between the sales price and the exercise
price. An optionee who sells the shares within two years after the grant date
or within one year after exercise will recognize ordinary compensation income
in an amount equal to the lesser of the difference between (a) the exercise
price and the fair market value of the shares on the date of exercise, or (b)
the exercise price and the sales proceeds. Any remaining gain or loss will be
treated as a capital gain or loss. Triad will be entitled to a federal income
tax deduction equal to the amount of ordinary compensation income recognized by
the optionee in this case. The deduction will be allowable at the same time the
optionee recognizes the income.
New Plan Benefits
The benefits that will be received by participants under the plan are not
determinable at this time. To date, no awards other than stock options have
been granted under the plan. Stock options to purchase shares of Triad common
stock granted to Triad's named executive officers under the plan with respect
to 1999 are summarized above. (See "Executive Compensation--Summary
Compensation Table.") During 1999, stock options to purchase 2,867,049 shares
of Triad common stock at an average weighted exercise price of $11.50 per share
were granted to all employees of Triad as a group.
On February 17, 2000, the compensation committee granted to the 172
employees participating in the plan in 2000, stock options to purchase
1,879,000 shares of Triad common stock at a price of $16.50 per share, the
closing price of Triad common stock on the Nasdaq National Market System on
such date.
The closing price of Triad common stock on the Nasdaq National Market System
on April 14, 2000 was $16.00 per share.
The Board of Directors recommends a vote "FOR" approval of the 1999 Long-
Term Incentive Plan.
4. APPROVAL OF TRIAD EMPLOYEE STOCK PURCHASE PLAN
Set forth below is a description of the Triad Hospitals, Inc. Employee Stock
Purchase Plan which was approved by the Triad Board on June 3, 1999. The plan
provides for the grant of stock options to employees of Triad and participating
subsidiaries to purchase shares of Triad common stock at below market prices
through payroll deductions. The purpose of the plan is to promote the interests
of Triad and its shareholders by strengthening Triad's ability to attract,
motivate and retain employees by providing such employees with a
19
<PAGE>
proprietary interest in Triad. It is intended that options issued pursuant to
the plan will constitute options issued pursuant to an "employee stock purchase
plan" within the meaning of section 423 of the Code. In order to receive
favorable tax treatment under section 423 of the Code, shareholder approval of
the plan is required. A brief description of the material features of the plan
is set forth below but is qualified by reference to the full text of the plan
attached as Exhibit B to this Proxy Statement.
Description of the Plan
Administration. The plan is administered by the compensation committee. The
compensation committee may from time to time adopt such rules and regulations
for carrying out the plan as it deems best. The compensation committee may
terminate or amend the plan at any time, subject to shareholder approval to the
extent deemed necessary to comply with section 423 of the Code. All of the
costs associated with administering and carrying out the plan are borne by
Triad.
Eligibility. Generally, all full-time and regular part-time employees of
Triad (or of any of its participating subsidiaries) who have completed three
months of employment with Triad (or any of its subsidiaries) are eligible to
receive options under the plan to purchase shares of Triad common stock. In no
event, however, may an employee be granted an option under the plan if the
employee, immediately after the option is granted, owns stock representing five
percent (5%) or more of the total combined voting power or value of all classes
of stock of Triad nor will an employee be granted an option which permits the
employee's rights to purchase Triad common stock under the plan and any similar
plans of Triad (or any parent or subsidiary corporations) to accrue at a rate
which exceeds $25,000 of fair market value of the stock (determined at the time
such option is granted) for each calendar year in which the option is
outstanding at any time.
Reservation of Shares. The total number of shares of Triad common stock that
may be issued pursuant to the plan is 3,000,000 shares, which may consist, in
whole or in part, of unissued shares or treasury shares. In the event of
certain corporate reorganizations, recapitalizations, or other specified
corporate transactions affecting Triad or the Triad common stock, proportionate
adjustments may be made to the number and kind of shares subject to the plan
and the option prices.
Options Grants. On the first business day of each payment period, Triad
grants to each participant an option to purchase, on the last business day of
the payment period, a number of shares of Triad common stock equal to (i) the
number of whole or fractional shares whose purchase price does not exceed ten
percent (10%) of the participant's covered compensation during the payment
period divided by (ii) the "option price" (as defined below). The six-month
periods, December 1 to May 31 and June 1 to November 30, are the payment
periods during which payroll deductions are accumulated under the plan.
Generally, the "option price" for each payment period is the lesser of (i) 85%
of the average market price of Triad's common stock on the first business day
of the payment period or (ii) 85% of the average market price of the Triad's
common stock on the last business day of the payment period.
Option Exercise. Each eligible employee who continues to be a participant in
the plan on the third Friday of the last month of a payment period is deemed to
have irrevocably stated the employee's intention to exercise the option on the
last business day of such payment period. The participant is deemed to have
purchased from Triad the number of whole or fractional shares of Triad's common
stock that could be purchased based on the participant's accumulated payroll
deductions during the payment period and the option price. If a participant is
not an employee on the third Friday of the last month of a payment period, the
participant is not entitled to exercise the option.
Payroll Deductions. An employee may authorize payroll deductions in a whole
percentage amount not less than one percent (1%) but not more than ten percent
(10%) of the employee's covered compensation received during the payment
period. Triad will accumulate and hold for the employee's account the amounts
deducted from the employee's pay. No interest will be paid on such amounts.
Deductions may be increased or decreased only at the beginning of a payment
period and an employee may change the contribution rate effective the first day
of a payment period. Once during each payment period, an employee may reduce
the
20
<PAGE>
contribution rate to 0% and may either allow dollars contributed to participate
in the allocation for such period or receive a refund prior to the allocation.
Withdrawal From Plan. An employee may withdraw from the plan at any time by
delivering a form of authorization indicating the employee's intent to
withdraw. If the authorization is received at least five (5) business days
prior to the third Friday of the last month of a payment period, Triad will
promptly refund the entire balance of the employee's deductions accumulated
during such period. If an employee's authorization is received after such date,
but before the end of a payment period, deductions will be stopped as soon as
practicable, and deductions accumulated during such period will be applied to
the purchase of stock. An employee who withdraws from the plan and who desires
to recommence participation is required to file a new authorization by the
third Friday of the last month of a payment period which cannot, however,
become effective before the beginning of the next payment period following the
employee's withdrawal.
Transferability. An employee's rights under the plan may not be transferred,
assigned to or availed of by any other person. Any option granted to an
employee may be exercised only by the employee.
Federal Income Tax Consequences
No federal income tax will be recognized by the participant upon an election
to participate in the plan or upon the purchase of shares of Triad's common
stock under the plan. If a participant disposes of shares of Triad's common
stock purchased under the plan within the later of (a) two years from the date
of grant of the option or (y) one year after the exercise date of such shares,
at the time of disposition the participant will recognize (i) ordinary income
equal to the fair market value of the shares on the exercise date, less the
amount paid for the shares, and (ii) a capital gain or loss equal to the
difference between the participant's basis in the shares (the amount paid for
the shares plus the amount taxed as ordinary income under subparagraph (i)
above) and the amount realized upon the disposition of the shares. A
participant must notify Triad if he or she disposes of any shares of Triad
common stock purchased under the plan within two years from the exercise date
of such shares. Generally, Triad will be allowed a corresponding deduction in
the same year and in the same amount required to be includible in the gross
income of the employee.
If a participant disposes of shares of Triad's common stock purchased under
the plan more than (a) two years from the date of grant of the option or (b)
one year after the exercise date of such shares, at the time of the disposition
the participant will recognize ordinary income equal to the lesser of (i) the
excess of the fair market value of the shares at the time of disposition over
the amount paid for the shares or (ii) the excess of the fair market value of
the shares on the date of grant over 85 percent of the fair market value of the
shares on the date of grant. In addition, the participant will recognize a
capital gain or loss equal to the difference between the participant's basis in
the shares (the amount paid for the shares plus the amount subject to tax as
ordinary income) and the amount realized upon the disposition of the shares.
Triad will not be allowed a corresponding deduction for the amount required to
be includible in the gross income of the employee.
The Board of Directors recommends a vote "FOR" approval of the Employee
Stock Purchase Plan.
5. ALL OTHER MATTERS THAT MAY COME BEFORE THE MEETING
As of the date of this statement, the Board of Directors knows of no
business that will be presented for consideration at the meeting other than
that referred to above. As to other business, if any, that may come before the
meeting, proxies in the enclosed form will be voted in accordance with the
judgment of the person or persons voting the proxies.
STOCKHOLDER NOMINATIONS AND PROPOSALS
The Board of Directors will receive at any time and will consider from time
to time suggestions from stockholders as to persons to be nominated by the
Board of Directors for election thereto by the stockholders or to be chosen by
the Board of Directors to fill newly created directorships or vacancies on the
Board of Directors.
21
<PAGE>
The Company's by-laws require that there be furnished to the Secretary of
the Company at the Company's principal executive offices written notice with
respect to the nomination of a person for election as a director (other than a
person nominated by or at the direction of the Board of Directors), as well as
the submission of a proposal (other than a proposal submitted by or at the
direction of the Board of Directors), at an annual meeting of stockholders. In
order for any such nomination or submission to be proper, the notice must
contain certain information concerning the nominating or proposing stockholder
and the nominee or the proposal, as the case may be, and must be delivered to
the Secretary of the Company at the Company's principal executive offices not
less than 90 days prior to the first anniversary of the preceding year's annual
meeting of stockholders; provided, however, that if the date of the annual
meeting is advanced more than 30 days prior to or delayed more than 60 days
after such anniversary date, notice by the stockholder to be timely must be
delivered not later than the close of business on the later of the 90th day
prior to such annual meeting or the tenth day following the day on which the
public announcement of the date of such meeting is first made.
In the event that the number of directors to be elected to the Board of
Directors is increased and there is no public announcement naming all of the
nominees for director or specifying the size of the increased Board of
Directors made by the Company at least 100 days prior to the first anniversary
of the preceding year's annual meeting, a stockholder's notice required by the
Company's by-laws shall also be considered timely, but only with respect to
nominees for any new positions created by such increase, if it is delivered not
later than the close of business on the tenth day following the day on which
such public announcement is first made by the Company.
Nominations by stockholders of persons for election to the Board of
Directors may be made at a special meeting of stockholders if the stockholder's
notice required by the Company's by-laws is delivered not later than the close
of business on the later of the 90 days prior to such special meeting or the
tenth day following the day on which public announcement is first made of the
date of the special meeting and of the nominees proposed by the Board of
Directors to be elected at such meeting.
A copy of the applicable by-law provisions may be obtained, without charge,
upon written request to the Secretary of the Company at the Company's principal
executive offices.
In accordance with the rules of the Securities and Exchange Commission, any
proposal of a stockholder intended to be presented at the Company's 2001 Annual
Meeting of Stockholders must be received by the Secretary of the Company before
December 25, 2000 in order for the proposal to be considered for inclusion in
the Company's notice of meeting, proxy statement and proxy relating to the 2001
Annual Meeting, scheduled for Tuesday, May 21, 2001.
22
<PAGE>
ADDITIONAL INFORMATION
At any time prior to their being voted, the enclosed proxies are revocable
by written notice to the Secretary of the Company or by appearance at the
meeting and voting in person. A quorum comprising the holders of a majority of
the outstanding shares of common stock on the record date must be present in
person or represented by proxy for the transaction of business at the 2000
Annual Meeting.
By order of the Board of Directors
Donald P. Fay
Executive Vice President, General
Counsel
and Secretary
April 24, 2000
A copy of our Annual Report on Form 10-K for the year ended December 31,
1999, excluding certain of the exhibits thereto, may be obtained without charge
by writing to Triad Hospitals, Inc., Investor Relations Department, 13455 Noel
Road, Suite 2000, Dallas, Texas 75240.
23
<PAGE>
EXHIBIT A
TRIAD HOSPITALS, INC.
1999 LONG-TERM INCENTIVE PLAN
1. Purpose of the Plan
The purpose of the Triad Hospitals, Inc. 1999 Long-Term Incentive Plan is to
promote the interests of the Corporation and its shareholders by strengthening
the Corporation's ability to attract, motivate, and retain personnel upon whose
judgment, initiative, and efforts the financial success and growth of the
business of the Corporation largely depend, to offer such personnel additional
incentives to put forth maximum efforts for the success of the business, and to
afford them an opportunity to acquire a proprietary interest in the Corporation
through stock ownership and other rights.
2. Definitions
Wherever the following capitalized terms are used in this Plan, they shall
have the meanings specified below:
(a) "Award" means an award of an Option, Restricted Stock Award, Stock
Appreciation Right, Performance Award, Phantom Stock Award or Dividend
Equivalent Award granted under the Plan.
(b) "Award Agreement" means an agreement entered into between the
Corporation and a Participant setting forth the terms and conditions of an
Award granted to a Participant.
(c) "Board" means the Board of Directors of the Corporation; provided,
however, that with regard to any action to be taken prior to the first meeting
of the Board of Directors of the Corporation, Board shall mean the Board of
Directors of Columbia/HCA.
(d) "Change in Control" shall have the meaning specified in Section 12
hereof.
(e) "Code" means the Internal Revenue Code of 1986, as amended.
(f) "Columbia/HCA" means the Columbia/HCA Healthcare Corporation, a Delaware
corporation.
(g) "Committee" means the committee appointed to administer the Plan and
shall consist of two or more directors of the Corporation (i) none of whom
shall be officers or employees of the Corporation, and (ii) all of whom, to the
extent deemed necessary or appropriate by the Board, shall satisfy the
requirements for an "outside director" under Section 162(m) and a "non-employee
director" within the meaning of Rule 16b-3 of the Securities Exchange Act of
1934. The members of the Committee shall be appointed by and serve at the
pleasure of the Board. Notwithstanding the foregoing, prior to the date
Columbia/HCA distributes all of its shares of the Corporation to the
shareholders of Columbia/HCA, Committee shall mean a committee of two or more
Directors of Columbia/HCA appointed to administer the plan (i) none of whom
shall be officers or employees of Columbia/HCA, and (ii) all of whom, to the
extent deemed necessary or appropriate by the Board of Columbia/HCA, shall
satisfy the requirements for an "outside director" under Section 162(m) and a
"non-employee director" within the meaning of Rule 16b-3 of the Securities
Exchange Act of 1934. If the applicable Board shall so direct, designated
members of the applicable Committee shall act as a separate subcommittee, which
shall administer the Plan as to all Section 162(m) Awards. In such event, all
references herein to the applicable Committee relating to Section 162(m) Awards
shall be considered to refer only to the applicable separate subcommittee.
A-1
<PAGE>
(h) "Common Stock" means the common stock of the Corporation.
(i) "Corporation" means Triad Hospitals, Inc., a Delaware corporation.
(j) "Date of Grant" means the date on which an Award under the Plan is made
by the Committee, or such later date as the Committee may specify to be the
effective date of the Award.
(k) "Dividend Equivalent Award" means an Award under Section 11 hereof
entitling the Participant to receive payments with respect to dividends
declared on the Common Stock.
(l) "Effective Date" means the Effective Date of this Plan, as defined in
Section 15.2 hereof.
(m) "Eligible Person" means any person who is an Employee of the Corporation
or any of its Subsidiaries and, in the case of Awards other than Incentive
Stock Options, any consultant or other independent contractor (not including
any non-employee outside director) providing services to the Corporation or a
Subsidiary.
(n) "Employee" means any person who is employed as a common-law employee.
(o) "Fair Market Value" of a share of Common Stock as of a given date shall
mean the closing sales price of the Common Stock on the Nasdaq Stock Market on
the trading day immediately preceding the date as of which the Fair Market
Value is to be determined, or, in the absence of any reported sales of Shares
on such date, on the first preceding date on which any such sale shall have
been reported (in either case, as reported in the Two Star Edition of The Wall
Street Journal). If the Common Stock is not listed on the Nasdaq Stock Market
on the date as of which Fair Market Value is to be determined, the Committee
shall in good faith determine the Fair Market Value in whatever manner it
considers appropriate.
(p) "Incentive Stock Option" means an option to purchase Common Stock that
is intended to qualify as an incentive stock option under section 422 of the
Code and the Treasury Regulations thereunder.
(q) "Non-qualified Stock Option" means an option to purchase Common Stock
that is not an Incentive Stock Option.
(r) "Option" means an Incentive Stock Option or a Non-qualified Stock Option
granted under Section 6 hereof.
(s) "Participant" means any Eligible Person who holds an outstanding Award
under the Plan.
(t) "Phantom Stock Award" means an Award under Section 10 hereof entitling a
Participant to a payment at the end of a vesting period of a unit value based
on the Fair Market Value of a share of Common Stock.
(u) "Plan" means the Triad Hospitals, Inc. 1999 Long-Term Incentive Plan as
set forth herein, as it may be amended from time to time.
(v) "Performance Award" means an Award under Section 9 hereof entitling a
Participant to a payment based on the Fair Market Value of a share of Common
Stock (a "Performance Share") or based on specified dollar units (a
"Performance Unit") at the end of a performance period, if certain conditions
established by the Committee are satisfied.
(w) "Restricted Stock Award" means an Award under Section 8 hereof entitling
a Participant to shares of Common Stock that are nontransferable and subject to
forfeiture until specific conditions established by the Committee are
satisfied.
(x) "Section 162(m)" means section 162(m) of the Code and the Treasury
Regulations thereunder.
(y) "Section 162(m) Award" means any Award that is intended to qualify for
the performance-based compensation exemption under Section 162(m).
(z) "Stock Appreciation Right" or "SAR" means an Award under Section 7
hereof entitling a Participant to receive an amount representing the difference
between the base price per share of the right and the Fair Market Value of a
share of Common Stock on the date of exercise.
A-2
<PAGE>
(aa) "Subsidiary" means an entity (whether or not a corporation) that is
wholly or majority owned or controlled, directly or indirectly, by the
Corporation, or any other affiliate of the Corporation that is so designated,
from time to time, by the Committee; provided, however, that with respect to
Incentive Stock Options, the term "Subsidiary" shall include only an entity
that qualifies under section 424(f) of the Code as a "subsidiary corporation"
with respect to the Corporation.
3. Shares of Common Stock Subject to the Plan
3.1. Number of Shares. Subject to the following provisions of this Section
3, the aggregate number of shares of Common Stock that may be issued pursuant
to all Awards under the Plan is 5,350,000 shares of Common Stock. The shares of
Common Stock to be delivered under the Plan will be made available from
authorized but unissued shares of Common Stock or issued shares that have been
reacquired by the Corporation. To the extent that any Award payable in Common
Stock is forfeited, cancelled, returned to the Corporation for failure to
satisfy vesting requirements or upon the occurrence of other forfeiture events,
or otherwise terminates without payment being made thereunder, shares of Common
Stock covered thereby will no longer be charged against the foregoing maximum
share limitations and may again be made subject to Awards under the Plan
pursuant to such limitations.
3.2. Adjustments. If there shall occur any recapitalization,
reclassification, stock dividend, stock split, reverse stock split, or other
distribution with respect to the shares of Common Stock, or other change in
corporate structure affecting the Common Stock, the Committee may, in the
manner and to the extent that it deems appropriate and equitable to the
Participants and consistent with the terms of this Plan, cause an adjustment to
be made in (i) the maximum number and kind of shares provided in Section 3.1
hereof, (ii) the maximum number and kind of shares set forth in Sections 6.1,
7.1, 8.1 and 9.4 hereof, (iii) the number and kind of shares of Common Stock,
share units, or other rights subject to then outstanding Awards, (iv) the price
for each share or unit or other right subject to then outstanding Awards, (v)
the performance targets or goals applicable to any outstanding Performance
Awards (subject to such limitations as are considered appropriate for Section
162(m) Awards), or (vi) any other terms of an Award that are affected by the
event. Notwithstanding the foregoing, in the case of Incentive Stock Options,
any such adjustments shall be made in a manner consistent with the requirements
of section 424(a) of the Code and, to the extent considered advisable by the
Committee, in a manner consistent with the requirements of Section 162(m).
4. Administration of the Plan
4.1. Committee Members. The Plan shall be administered by the Committee. The
Committee shall have such powers and authority as may be necessary or
appropriate for the Committee to carry out its functions as described in the
Plan. No member of the Committee shall be liable for any action or
determination made in good faith by the Committee with respect to the Plan or
any Award thereunder.
4.2. Discretionary Authority. Subject to the express limitations of the
Plan, the Committee shall have authority in its discretion to determine the
Eligible Persons to whom, and the time or times at which, Awards may be
granted, the number of shares, units or other rights subject to each Award, the
exercise, base or purchase price of an Award (if any), the time or times at
which an Award will become vested, exercisable or payable, the performance
criteria, performance goals and other conditions of an Award, the duration of
the Award, and all other terms of the Award. The Committee shall also have
discretionary authority to interpret the Plan, to make all factual
determinations under the Plan, and to make all other determinations necessary
or advisable for Plan administration. The Committee may prescribe, amend, and
rescind rules and regulations relating to the Plan. All interpretations,
determinations, and actions by the Committee shall be final, conclusive, and
binding upon all parties.
4.3. Changes to Awards. The Committee shall have the authority to effect, at
any time and from time to time, (i) the cancellation of any or all outstanding
Awards and the grant in substitution therefor of new Awards covering the same
or different numbers of shares of Common Stock and having an exercise or base
price which
A-3
<PAGE>
may be the same as or different than the exercise or base price of the
cancelled Awards, or (ii) the amendment of the terms of any and all outstanding
Awards; provided, however, that no such action by the Committee may adversely
impair the rights of a Participant (or any permitted transferee) under any
outstanding Award without the consent of the Participant (or transferee). The
Committee may in its discretion accelerate the vesting or exercisability of an
Award at any time or on the basis of any specified event.
5. Eligibility and Awards
All Eligible Persons are eligible to be designated by the Committee to
receive an Award under the Plan. The Committee has authority, in its sole
discretion, to determine and designate from time to time those Eligible Persons
who are to be granted Awards, the types of Awards to be granted and the number
of shares or units subject to the Awards that are granted under the Plan. Each
Award will be evidenced by an Award Agreement between the Corporation and the
Participant that shall include such terms and conditions (consistent with the
Plan) as the Committee may determine; provided, however, that failure to issue
an Award Agreement shall not invalidate an Award.
6. Stock Options
6.1. Grant of Option. An Option may be granted to any Eligible Person
selected by the Committee; provided, however, that only Employees of the
Corporation or a Subsidiary shall be eligible to receive Incentive Stock
Options. Subject to the applicable provisions of section 422 of the Code, each
Option shall be designated, in the discretion of the Committee, as an Incentive
Stock Option or a Non-qualified Stock Option. The maximum number of shares of
Common Stock that may be granted under Options to any Participant during any
calendar year shall be limited to 700,000 shares (subject to adjustment as
provided in Section 3.2 hereof).
6.2. Exercise Price. The exercise price under any Option shall be determined
by the Committee; provided, however, that the exercise price per share under an
Option shall not be less than 100 percent of the Fair Market Value per share of
the Common Stock on the Date of Grant.
6.3. Vesting; Term of Option. The Committee, in its sole discretion, shall
prescribe the time or times at which, or the conditions upon which, an Option
or portion thereof shall become vested and exercisable, and may accelerate the
exercisability of any Option at any time. The period during which a vested
Option may be exercised shall be ten years from the Date of Grant, unless a
shorter exercise period is specified by the Committee in an Award, subject to
such limitations as may apply under an Award relating to the termination of a
Participant's employment or other service with the Corporation or any
Subsidiary.
6.4. Option Exercise; Withholding. Subject to such terms and conditions as
shall be specified in an Award, an Option may be exercised in whole or in part
at any time during the term thereof by written notice to the Corporation,
together with payment of the aggregate exercise price therefor. Payment of the
exercise price shall be made (i) in cash or by cash equivalent, (ii) at the
discretion of the Committee, in shares of Common Stock acceptable to the
Committee, valued at the Fair Market Value of such shares on the date of
exercise, (iii) at the discretion of the Committee, by a delivery of a notice
that the Participant has placed a market sell order (or similar instruction)
with a broker with respect to shares of Common Stock then issuable upon
exercise of the Option, and that the broker has been directed to pay a
sufficient portion of the net proceeds of the sale to the Corporation in
satisfaction of the Option exercise price (conditioned upon the payment of such
net proceeds), (iv) at the discretion of the Committee, by a combination of the
methods described above, or (v) by such other method as may be approved by the
Committee and set forth in the Award. In addition to and at the time of payment
of the exercise price, the Participant shall pay to the Corporation the full
amount of any and all applicable income tax and employment tax amounts required
to be withheld in connection with such exercise, payable under such of the
methods described above for the payment of the exercise price of the Options as
may be approved by the Committee.
A-4
<PAGE>
6.5. Limited Transferability of Non-qualified Options. All Options shall be
nontransferable except (i) upon the Participant's death, by the Participant's
will or the laws of descent and distribution or (ii) in the case Non-qualified
Stock Options only, on a case-by-case basis as may be approved by the Committee
in its discretion, in accordance with the terms provided below. An Award
Agreement for a Non-qualified Stock Option may provide that the Participant
shall be permitted to, during his or her lifetime and subject to the prior
approval of the Committee at the time of proposed transfer, transfer all or
part of the Option to the Participant's family member (as defined in the Award
Agreement in a manner consistent with the requirements for the Form S-8
registration statement, if applicable). Any such transfer shall be subject to
the condition that it is made by the Participant for estate planning, tax
planning, donative purposes or pursuant to a domestic relations order, and no
consideration (other than nominal consideration) is received by the Participant
therefor. The transfer of a Non-qualified Stock Option may be subject to such
other terms and conditions as the Committee may in its discretion impose from
time to time, including a condition that the portion of the Option to be
transferred be vested and exercisable by the Participant at the time of the
transfer. Subsequent transfers of an Option shall be prohibited other than by
will or the laws of descent and distribution upon the death of the transferee.
6.6. Additional Rules for Incentive Stock Options.
(a) Annual Limits. No Incentive Stock Option shall be granted to a
Participant as a result of which the aggregate Fair Market Value (determined as
of the Date of Grant) of the stock with respect to which Incentive Stock
Options are exercisable for the first time in any calendar year under the Plan
and any other stock option plans of the Corporation, any Subsidiary, or any
parent corporation, would exceed the maximum amount permitted under section
422(d) of the Code. This limitation shall be applied by taking Options into
account in the order in which granted.
(b) Termination of Employment. An Award of an Incentive Stock Option may
provide that such Option may be exercised not later than 3 months following
termination of employment of the Participant with the Corporation and all
Subsidiaries, subject to special rules relating to death and disability, as and
to the extent determined by the Committee to be appropriate with regard to the
requirements of section 422 of the Code and Treasury Regulations thereunder.
(c) Other Terms and Conditions; Nontransferability. Any Incentive Stock
Option granted hereunder shall contain such additional terms and conditions,
not inconsistent with the terms of this Plan, as are deemed necessary or
desirable by the Committee, which terms, together with the terms of this Plan,
shall be intended and interpreted to cause such Incentive Stock Option to
qualify as an "incentive stock option" under section 422 of the Code. Such
terms shall include, if applicable, limitations on Incentive Stock Options
granted to ten-percent owners of the Corporation. An Award Agreement for an
Incentive Stock Option may provide that such Option shall be treated as a Non-
qualified Stock Option to the extent that certain requirements applicable to
"incentive stock options" under the Code shall not be satisfied. An Incentive
Stock Option shall by its terms be nontransferable otherwise than by will or by
the laws of descent and distribution, and shall be exercisable during the
lifetime of a Participant only by such Participant.
(d) Disqualifying Dispositions. If shares of Common Stock acquired by
exercise of an Incentive Stock Option are disposed of within two years
following the Date of Grant or one year following the transfer of such shares
to the Participant upon exercise, the Participant shall, promptly following
such disposition, notify the Corporation in writing of the date and terms of
such disposition and provide such other information regarding the disposition
as the Committee may reasonably require.
6.7. Restrictions on Transfer of Stock. The Committee may, in its sole
discretion, impose in any Award of an Option restrictions on the
transferability of the shares of Common Stock issued upon exercise of such
Option. If any such restrictions are imposed, the Committee may require the
Participant to enter into an escrow agreement providing that the certificates
representing the shares subject to such transfer restrictions will remain in
the physical custody of an escrow holder until such restrictions are removed or
have expired. The Committee may require that certificates representing the
shares subject to such restrictions bear a legend making
A-5
<PAGE>
appropriate reference to the restrictions imposed. Subject to any restrictions
imposed in accordance with this Section 6.7, the Participant will have all
rights of a shareholder with respect to any such shares acquired upon an Option
exercise, including the right to vote the shares and receive all dividends and
other distributions paid or made with respect thereto.
7. Stock Appreciation Rights
7.1. Grant of SARs. A Stock Appreciation Right granted to a Participant is
an Award in the form of a right to receive, upon surrender of the right but
without other payment, an amount based on appreciation in the Fair Market Value
of the Common Stock over a base price established for the Award, exercisable at
such time or times and upon conditions as may be approved by the Committee. The
maximum number of shares of Common Stock that may be subject to SARs granted to
any Participant during any calendar year shall be limited to 700,000 shares
(subject to adjustment as provided in Section 3.2 hereof).
7.2. Tandem SARs. A Stock Appreciation Right may be granted in connection
with an Option, either at the time of grant or at any time thereafter during
the term of the Option. An SAR granted in connection with an Option will
entitle the holder, upon exercise, to surrender such Option or any portion
thereof to the extent unexercised, with respect to the number of shares as to
which such SAR is exercised, and to receive payment of an amount computed as
described in Section 7.4 hereof. Such Option will, to the extent and when
surrendered, cease to be exercisable. An SAR granted in connection with an
Option hereunder will have a base price per share equal to the per share
exercise price of the Option, will be exercisable at such time or times, and
only to the extent, that a related Option is exercisable, and will expire no
later than the related Option expires.
7.3. Freestanding SARs. A Stock Appreciation Right may be granted without
any related Option, and in such case, will be exercisable as determined by the
Committee, but in no event after 10 years from the Date of Grant. The base
price of an SAR granted without any related Option shall be determined by the
Committee in its sole discretion; provided, however, that the base price per
share of any such freestanding SAR shall not be less than 100 percent of the
Fair Market Value of the Common Stock on the Date of Grant.
7.4. Payment of SARs. An SAR will entitle the holder, upon exercise of the
SAR, to receive payment of an amount determined by multiplying: (i) the excess
of the Fair Market Value of a share of Common Stock on the date of exercise of
the SAR over the base price of such SAR, by (ii) the number of shares as to
which such SAR is exercised. Payment of the amount determined under the
foregoing may be made, in the discretion of the Committee, in cash, in shares
of Common Stock valued at their Fair Market Value on the date of exercise, or
in a combination of cash and shares of Common Stock.
8. Restricted Stock Award
8.1. Grant of Restricted Stock Awards. An Award of Restricted Stock to a
Participant represents shares of Common Stock that are issued subject to such
restrictions on transfer and other incidents of ownership and such forfeiture
conditions as the Committee may determine. The Committee may, in connection
with any Restricted Stock Award, require the payment of a specified purchase
price. The Committee may grant a Restricted Stock Award that is a Section
162(m) Award (as described in Section 8.2 below), as well as Restricted Stock
Awards that are not Section 162(m) Awards; provided, however, that the maximum
number of shares of Common Stock that may be subject to a Restricted Stock
Award granted to a Participant during any one calendar year shall be separately
limited to 280,000 shares (subject to adjustment as provided in Section 3.2
hereof).
8.2. Vesting Requirements. The restrictions imposed on shares granted under
a Restricted Stock Award shall lapse in accordance with the vesting
requirements specified by the Committee in the Award Agreement. Such vesting
requirements may be based on the continued employment of the Participant with
the Corporation or its Subsidiaries for a specified time period or periods,
provided that any such restriction shall not be
A-6
<PAGE>
scheduled to lapse in its entirety earlier than the first anniversary of the
Date of Grant. Such vesting requirements may also be based on the attainment of
specified business goals or measures established by the Committee in its sole
discretion. In the case of any Restricted Stock Award that is a Section 162(m)
Award, any such performance-based vesting requirements shall be based upon the
performance criteria identified in Section 9.3 below, and the terms of the
Award shall otherwise comply with the Section 162(m) requirements described in
Section 9.4 hereof.
8.3. Restrictions. Shares granted under any Restricted Stock Award may not
be transferred, assigned or subject to any encumbrance, pledge, or charge until
all applicable restrictions are removed or have expired, unless otherwise
allowed by the Committee. The Committee may require the Participant to enter
into an escrow agreement providing that the certificates representing the
shares granted or sold under a Restricted Stock Award will remain in the
physical custody of an escrow holder until all restrictions are removed or have
expired. Failure to satisfy any applicable restrictions shall result in the
subject shares of the Restricted Stock Award being forfeited and returned to
the Corporation, with any purchase price paid by the Participant to be
refunded, unless otherwise provided by the Committee. The Committee may require
that certificates representing the shares granted under a Restricted Stock
Award bear a legend making appropriate reference to the restrictions imposed.
8.4. Rights as Shareholder. Subject to the foregoing provisions of this
Section 8 and the applicable Award Agreement, the Participant will have all
rights of a shareholder with respect to the shares granted to him under a
Restricted Stock Award, including the right to vote the shares and receive all
dividends and other distributions paid or made with respect thereto, unless the
Committee determines otherwise at the time the Restricted Stock Award is
granted.
8.5. Section 83(b) Election. The Committee may provide in an Award Agreement
that the Restricted Stock Award is conditioned upon the Participant's
refraining from making an election with respect to the Award under section
83(b) of the Code. Irrespective of whether an Award is so conditioned, if a
Participant makes an election pursuant to section 83(b) of the Code with
respect to a Restricted Stock Award, the Participant shall be required to
promptly file a copy of such election with the Corporation.
9. Performance Awards
9.1. Grant of Performance Awards. The Committee may grant Performance Awards
under the Plan, which shall be represented by units denominated on the Date of
Grant either in shares of Common Stock (Performance Shares) or in dollars
(Performance Units). The Committee may grant Performance Awards that are
Section 162(m) Awards, as well as Performance Awards that are not Section
162(m) Awards. At the time a Performance Award is granted, the Committee shall
determine, in its sole discretion, one or more performance periods and
performance goals to be achieved during the applicable performance periods, as
well as such other restrictions and conditions as the Committee deems
appropriate. In the case of Performance Units, the Committee shall also
determine a target unit value or a range of unit values for each Award. No
performance period shall exceed ten years from the Date of Grant. The
performance goals applicable to a Performance Award grant may be subject to
such later revisions as the Committee shall deem appropriate to reflect
significant unforeseen events, such as changes in law, accounting practices or
unusual or nonrecurring items or occurrences. The Committee's authority to make
such adjustments shall be subject to such limitations as the Committee deems
appropriate in the case of a Performance Award that is a Section 162(m) Award.
9.2. Payment of Performance Awards. At the end of the performance period,
the Committee shall determine the extent to which performance goals have been
attained, or a degree of achievement between minimum and maximum levels, in
order to establish the level of payment to be made, if any, and shall determine
if payment is to be made in the form of cash or shares of Common Stock (valued
at their Fair Market Value at the time of payment) or a combination of cash and
shares of Common Stock. Payments of Performance Awards shall generally be made
as soon as practicable following the end of the performance period.
A-7
<PAGE>
9.3. Performance Criteria. The performance criteria upon which the payment
or vesting of a Performance Award that is a Section 162(m) Award may be based
shall be limited to one or more of the following business measures, which may
be applied with respect to the Corporation, any Subsidiary or any business
unit, and which may be measured on an absolute or relative to peer-group basis:
(i) total shareholder return, (ii) stock price increase, (iii) return on
equity, (iv) return on capital, (v) earnings per share, (vi) EBIT (earnings
before interest and taxes), and (vii) cash flow (including operating cash flow,
free cash flow, discounted cash flow return on investment, and cash flow in
excess of costs of capital). In the case of Performance Awards that are not
Section 162(m) Awards, the Committee shall designate performance criteria from
among the foregoing or such other business criteria as it shall determine in
its sole discretion.
9.4. Section 162(m) Requirements. In the case of a Performance Award that is
a Section 162(m) Award, the Committee shall make all determinations necessary
to establish the terms of the Award within 90 days of the beginning of the
performance period (or such other time period as is required under Section
162(m)), including, without limitation, the designation of the Participant to
whom the Performance Award is to be made, the performance criteria or criterion
applicable to the Award and the performance goals that relate to such criteria,
and the dollar amounts or number of shares of Common Stock payable upon
achieving the applicable performance goals. As and to the extent required by
Section 162(m), the terms of a Performance Award that is a Section 162(m) Award
must state, in terms of an objective formula or standard, the method of
computing the amount of compensation payable under the Award, and must preclude
discretion to increase the amount of compensation payable under the terms of
the Award (but may give the Committee discretion to decrease the amount of
compensation payable). The maximum amount of compensation that may be payable
to a Participant during any one calendar year under a Performance Unit Award
shall be $4.2 million. The maximum number of Common Stock units that may be
subject to a Performance Share Award granted to a Participant during any one
calendar year shall be 280,000 share units (subject to adjustment as provided
in Section 3.2 hereof).
10. Phantom Stock Award
10.1. Grant of Phantom Stock Awards. A Phantom Stock Award is an Award to a
Participant of a number of hypothetical share units with respect to shares of
Common Stock, with an initial value based on the Fair Market Value of the
Common Stock on the Date of Grant. A Phantom Stock Award shall be subject to
such restrictions and conditions as the Committee shall determine. On the Date
of Grant, the Committee shall determine, in its sole discretion, the
installment or other vesting period of the Phantom Stock Award and the maximum
value of the Phantom Stock Award, if any. No vesting period shall exceed 10
years from the Date of Grant. A Phantom Stock Award may be granted, at the
discretion of the Committee, together with a Dividend Equivalent Award covering
the same number of shares.
10.2. Payment of a Phantom Stock Awards. Upon the vesting date or dates
applicable to the Phantom Stock Award granted to a Participant, an amount equal
to the Fair Market Value of one share of Common Stock upon such vesting dates
(subject to any applicable maximum value) shall be paid with respect to each
Phantom Stock Award unit granted to the Participant. Payment may be made, at
the discretion of the Committee, in cash or in shares of Common Stock valued at
their Fair Market Value on the applicable vesting dates, or in a combination
thereof.
11. Dividend Equivalent Award
11.1. Grant of a Dividend Equivalent Awards. A Dividend Equivalent Award
granted to a Participant is an Award in the form of a right to receive cash
payments determined by reference to dividends declared on the Common Stock from
time to time during the term of the Award, which shall not exceed 10 years from
the Date of Grant. Dividend Equivalent Awards may be granted on a stand-alone
basis or in tandem with other Awards. Dividend Equivalent Awards granted on a
tandem basis shall expire at the time the underlying Award is exercised or
otherwise becomes payable to the Participant, or expires.
11.2. Payment of Dividend Equivalent Awards. Dividend Equivalent Awards
shall be payable in cash or in shares of Common Stock, valued at their Fair
Market Value on either the date the related dividends are
A-8
<PAGE>
declared or the date the Dividend Equivalent Awards are paid to a Participant,
as determined by the Committee. Dividend Equivalent Awards shall be payable to
a Participant as soon as practicable following the time dividends are declared
and paid with respect to the Common Stock, or at such later date as the
Committee shall specify in the Award Agreement. Dividend Equivalent Awards
granted with respect to Options intended to qualify as a Section 162(m) Award
shall be payable regardless of whether the Option is exercised.
12. Change in Control
12.1. Effect of Change in Control. The Committee may, in an Award Agreement,
provide for the effect of a Change in Control on an Award. Such provisions may
include any one or more of the following: (i) the acceleration or extension of
time periods for purposes of exercising, vesting in, or realizing gain from any
Award, (ii) the elimination or modification of performance or other conditions
related to the payment or other rights under an Award, (iii) provision for the
cash settlement of an Award for an equivalent cash value, as determined by the
Committee, or (iv) such other modification or adjustment to an Award as the
Committee deems appropriate to maintain and protect the rights and interests of
Participants upon or following a Change in Control.
12.2. Definition of Change in Control. For purposes hereof, a "Change in
Control" shall be deemed to have occurred upon the occurrence of any of the
following after the date on which the Corporation becomes a publicly-held
Corporation:
(i) An acquisition (other than directly from the Corporation) of any
voting securities of the Corporation (the "Voting Securities") by any
"Person" (as the term Person is used for purposes of Section 13(d) or 14(d)
of the Securities Exchange Act of 1934, as amended (the "1934 Act"))
immediately after which such Person has "Beneficial Ownership" (within the
meaning of Rule 13d-3 promulgated under the 1934 Act) of twenty percent
(20%) or more of the combined voting power of the then outstanding Voting
Securities; provided, however, that in determining whether a Change in
Control has occurred, Voting Securities which are acquired in a "Non-
Control Acquisition" (as hereinafter defined) shall not constitute an
acquisition which would cause a Change in Control. A "Non-Control
Acquisition" shall mean an acquisition by (i) an employee benefit plan (or
a trust forming a part thereof) maintained by (A) the Corporation or (B)
any corporation or other Person of which a majority of the voting power or
the equity securities or equity interests is owned directly or indirectly
by the Corporation (a "Control Subsidiary"), or (ii) the Corporation or any
Control Subsidiary.
(ii) The individuals who, as of the date the Corporation issues any
class of equity securities required to be registered under Section 12 of
the 1934 Act, are members of the Board (the "Incumbent Board"), cease for
any reason to constitute at least two-thirds of the Board; provided,
however, that if the election or nomination for election by the
Corporation's stockholders of any new director was approved by a vote of at
least two-thirds of the Incumbent Board, such new director shall, for
purposes of this Agreement, be considered as a member of the Incumbent
Board; provided, further, however, that no individual shall be considered a
member of the Incumbent Board if (1) such individual initially assumed
office as a result of either an actual or threatened "Election Contest" (as
described in Rule 14a-11 promulgated under the 1934 Act) or other actual or
threatened solicitation of proxies or consents by or on behalf of a Person
other than the Board (a "Proxy Contest") including by reason of any
agreement intended to avoid or settle any Election Contest or Proxy Contest
or (2) such individual was designated by a Person who has entered into an
agreement with the Corporation to effect a transaction described in clause
(i) or (iii) of this Section 12.2; or
(iii) Consummation, after approval by stockholders of the Corporation,
of:
(1) A merger, consolidation or reorganization involving the
Corporation, unless,
(A) The stockholders of the Corporation, immediately before such
merger, consolidation or reorganization, own, directly or indirectly
immediately following such merger, consolidation or reorganization,
at least seventy-five percent (75%) of the combined voting power of
the
A-9
<PAGE>
outstanding Voting Securities of the corporation resulting from such
merger or consolidation or reorganization or its parent corporation
(the "Surviving Corporation") in substantially the same proportion
as their ownership of the Voting Securities immediately before such
merger, consolidation or reorganization;
(B) The individuals who were members of the Incumbent Board
immediately prior to the execution of the agreement providing for
such merger, consolidation or reorganization constitute at least
two-thirds of the members of the board of directors of the Surviving
Corporation; and
(C) No Person (other than the Corporation, any Control
Subsidiary, any employee benefit plan (or any trust forming a part
thereof) maintained by the Corporation, the Surviving Corporation or
any Control Subsidiary, or any Person who, immediately prior to such
merger, consolidation or reorganization, had Beneficial Ownership of
twenty percent (20%) or more of the then outstanding Voting
Securities) has Beneficial Ownership of twenty percent (20%) or more
of the combined voting power of the Surviving Corporation's then
outstanding Voting Securities.
(2) A complete liquidation or dissolution of the Corporation; or
(3) The sale or other disposition of all or substantially all of the
assets of the Corporation to any Person (other than a transfer to a
Control Subsidiary).
Notwithstanding the foregoing, a Change in Control shall not be deemed to
occur solely because any Person (the "Subject Person") acquired Beneficial
Ownership of more than the permitted amount of the outstanding Voting
Securities as a result of the acquisition of Voting Securities by the
Corporation which, by reducing the number of Voting Securities outstanding,
increased the proportional number of shares Beneficially Owned by the Subject
Person, provided that if a Change in Control would occur (but for the operation
of this sentence) as a result of the acquisition of Voting Securities by the
Corporation, and after such share acquisition by the Corporation, the Subject
Person becomes the Beneficial Owner of any additional Voting Securities which
increases the percentage of the then outstanding Voting Securities Beneficially
Owned by the Subject Person, then a Change in Control shall occur.
13. Award Agreements
13.1. Form of Agreement. Each Award under this Plan shall be evidenced by an
Award Agreement in a form approved by the Committee setting forth the number of
shares of Common Stock, units or other rights (as applicable) subject to the
Award, the exercise, base, or purchase price (if any) of the Award, the time or
times at which an Award will become vested, exercisable or payable, the
duration of the Award, and in the case of Performance Awards, the applicable
performance criteria and goals. The Award Agreement shall also set forth other
material terms and conditions applicable to the Award as determined by the
Committee consistent with the limitations of this Plan. Award Agreements
evidencing Awards that are Section 162(m) Awards shall contain such terms and
conditions as may be necessary to meet the applicable requirements of Section
162(m). Award Agreements evidencing Incentive Stock Options shall contain such
terms and conditions as may be necessary to meet the applicable provisions of
section 422 of the Code.
13.2. Forfeiture Events. The Committee may specify in an Award that the
Participant's rights, payments and benefits with respect to an Award shall be
subject to reduction, cancellation, forfeiture or recoupment upon the
occurrence of certain specified events, in addition to any otherwise applicable
vesting or performance conditions of an Award. Such events shall include, but
shall not be limited to, termination of employment for cause, violation of
material Corporation or Subsidiary policies, breach of noncompetition,
confidentiality or other restrictive covenants that may apply to the
Participant, or other conduct by the Participant that is detrimental to the
business or reputation of the Corporation or any Subsidiary.
A-10
<PAGE>
14. General Provisions
14.1. No Assignment or Transfer; Beneficiaries. Except as provided in
Section 6.5 hereof, Awards under the Plan shall not be assignable or
transferable, except by will or by the laws of descent and distribution, and
during the lifetime of a Participant, the Award shall be exercised only by such
Participant or by his guardian or legal representative. Notwithstanding the
foregoing, the Committee may provide in the terms of an Award Agreement that
the Participant shall have the right to designate a beneficiary or
beneficiaries who shall be entitled to any rights, payments or other specified
under an Award following the Participant's death.
14.2. Deferrals of Payment. Notwithstanding any other provisions of the
Plan, the Committee may permit a Participant to defer the receipt of payment of
cash or delivery of shares of Common Stock that would otherwise be due to the
Participant by virtue of the exercise of a right or the satisfaction of vesting
or other conditions with respect to an Award. If any such deferral is to be
permitted by the Committee, the Committee shall establish the rules and
procedures relating to such deferral, including, without limitation, the period
of time in advance of payment when an election to defer may be made, the time
period of the deferral and the events that would result in payment of the
deferred amount, the interest or other earnings attributable to the deferral
and the method of funding, if any, attributable to the deferred amount.
14.3. Rights as Shareholder. A Participant shall have no rights as a holder
of Common Stock with respect to any unissued securities covered by an Award
until the date the Participant becomes the holder of record of such securities.
Except as provided in Section 3.2 hereof, no adjustment or other provision
shall be made for dividends or other shareholder rights, except to the extent
that the Award Agreement is a Dividend Equivalent Award, or otherwise provides
for dividend payments or similar economic benefits.
14.4. Employment or Service. Nothing in the Plan, in the grant of any Award
or in any Award Agreement shall confer upon any Eligible Person the right to
continue in the capacity in which he is employed by, or otherwise serves, the
Corporation or any Subsidiary.
14.5. Securities Laws. No shares of Common Stock will be issued or
transferred pursuant to an Award unless and until all then applicable
requirements imposed by federal and state securities and other laws, rules and
regulations and by any regulatory agencies having jurisdiction, and by any
stock exchanges upon which the Common Stock may be listed, have been fully met.
As a condition precedent to the issuance of shares pursuant to the grant or
exercise of an Award, the Corporation may require the Participant to take any
reasonable action to meet such requirements. The Committee may impose such
conditions on any shares of Common Stock issuable under the Plan as it may deem
advisable, including, without limitation, restrictions under the Securities Act
of 1933, as amended, under the requirements of any stock exchange upon which
such shares of the same class are then listed, and under any blue sky or other
securities laws applicable to such shares.
14.6. Tax Withholding. The Participant shall be responsible for payment of
any taxes or similar charges required by law to be withheld from an Award or an
amount paid in satisfaction of an Award, which shall be paid by the Participant
on or prior to the payment or other event that results in taxable income in
respect of an Award. The Award Agreement shall specify the manner in which the
withholding obligation shall be satisfied with respect to the particular type
of Award.
14.7. Unfunded Plan. The adoption of this Plan and any setting aside of cash
amounts or shares of Common Stock by the Corporation with which to discharge
its obligations hereunder shall not be deemed to create a trust or other funded
arrangement. The benefits provided under this Plan shall be a general,
unsecured obligation of the Corporation payable solely from the general assets
of the Corporation, and neither a Participant nor the Participant's permitted
transferees or estate shall have any interest in any assets of the Corporation
by virtue of this Plan, except as a general unsecured creditor of the
Corporation. Notwithstanding the foregoing, the Corporation shall have the
right to implement or set aside funds in a grantor trust, subject to the claims
of the Corporation's creditors, to discharge its obligations under the Plan.
A-11
<PAGE>
14.8. Other Compensation and Benefit Plans. The adoption of the Plan shall
not affect any other stock incentive or other compensation plans in effect for
the Corporation or any Subsidiary, nor shall the Plan preclude the Corporation
from establishing any other forms of stock incentive or other compensation for
employees of the Corporation or any Subsidiary. The amount of any compensation
deemed to be received by a Participant pursuant to an Award shall not
constitute compensation with respect to which any other employee benefits of
such Participant are determined, including, without limitation, benefits under
any bonus, pension, profit sharing, life insurance or salary continuation plan,
except as otherwise specifically provided by the terms of such plan.
14.9. Plan Binding on Transferees. The Plan shall be binding upon the
Corporation, its transferees and assigns, and the Participant, his executor,
administrator and permitted transferees and beneficiaries.
14.10. Construction and Interpretation. Whenever used herein, nouns in the
singular shall include the plural, and the masculine pronoun shall include the
feminine gender. Headings of Articles and Sections hereof are inserted for
convenience and reference and constitute no part of the Plan.
14.11. Severability. If any provision of the Plan or any Award Agreement
shall be determined to be illegal or unenforceable by any court of law in any
jurisdiction, the remaining provisions hereof and thereof shall be severable
and enforceable in accordance with their terms, and all provisions shall remain
enforceable in any other jurisdiction.
14.12. Governing Law. The validity and construction of this Plan and of the
Award Agreements shall be governed by the laws of the State of Texas.
15. Effective Date, Termination and Amendment
15.1. Establishment of the Plan. This Plan is being adopted by the Board in
connection with the anticipated formation of the Corporation as a Subsidiary of
Columbia/HCA and the distribution shortly thereafter by Columbia/HCA of all of
its shares of the Corporation to the shareholders of Columbia/HCA.
15.2. Effective Date; Shareholder Approval. The Effective Date of the Plan
shall be the date the Corporation's Common Stock is distributed to Columbia/HCA
Healthcare Corporation stockholders; provided, however, that no amounts may be
paid or shares issued under any Award granted on or after the first meeting of
the shareholders of the Corporation that shall occur more than twelve months
after the date on which the Corporation becomes a publicly held corporation,
unless the shareholders of the Corporation shall have approved the Plan. At the
sole discretion of the Board, in order to comply with the requirements of
Section 162(m) for certain types of Awards under the Plan, the performance
criteria set forth in Section 9.3 shall be reapproved by the shareholders of
the Corporation no later than the first shareholder meeting that occurs in the
fifth calendar year following the calendar year of the initial shareholder
approval of such performance criteria.
15.3. Termination. The Plan shall terminate on the date immediately
preceding the tenth anniversary of the date the Plan is adopted by the Board.
The Board may, in its sole discretion and at any earlier date, terminate the
Plan. Notwithstanding the foregoing, no termination of the Plan shall adversely
affect any Award theretofore granted without the consent of the Participant or
the permitted transferee of the Award.
15.4. Amendment. The Board may at any time and from time to time and in any
respect, amend or modify the Plan; provided, however, that no amendment or
modification of the Plan shall be effective without the consent of the
Corporation's shareholders that would (i) change the class of Eligible Persons
under the Plan, (ii) increase the number of shares of Common Stock reserved for
issuance under the Plan in accordance with Section 3.1 hereof, or (iii) allow
the grant of Options at an exercise price below Fair Market Value. In addition,
the Board may seek the approval of any amendment or modification by the
Corporation's shareholders to the extent it deems necessary or advisable in its
sole discretion for purposes of compliance with Section 162(m) or section 422
of the Code, the listing requirements of the Nasdaq Stock Market or for any
other purpose. No amendment or modification of the Plan shall adversely affect
any Award theretofore granted without the consent of the Participant or the
permitted transferee of the Award.
A-12
<PAGE>
Appendix A
Notwithstanding anything elsewhere in the Plan to the contrary, the
following rules shall apply in connection with the distribution of Common Stock
to Columbia/HCA stockholders (the "Spin-off").
(i) In the case of each Columbia/HCA Non-Qualified Option that is a vested
option and covers more than 1000 shares, the Committee may grant an
option which covers a number of shares of Common Stock equal to the
Original Number of Shares multiplied by the Triad Share Multiple and
which has a per share exercise price equal to the per share exercise
price of the original Columbia/HCA Non-Qualified Option multiplied by
the Triad Ratio.
(ii) In the case of each Columbia/HCA ISO that is held by a Triad Employee
or Triad Terminee (or his estate), the Committee may grant an option
which covers a number of shares of Common Stock equal to the Original
Number of Shares divided by the Triad Ratio and (2) has a per share
exercise price equal to the original per share exercise price
multiplied by the Triad Ratio.
(iii) In the case of any options granted by the Committee pursuant to this
Appendix, any resulting per share exercise price which is not equal
to a whole multiple of a cent shall be rounded up to the next whole
cent and any resulting number of shares covered by an option which is
not equal to a whole multiple of a share shall be rounded down to the
next whole share.
(iv) The Committee may provide that the terms of any option granted under
this Appendix are to be substantially the same as those of the related
Columbia/HCA Option, subject to such exceptions as the Committee may
provide. Any such option may, in the discretion of the Committee, also
provide that (a) any period of prior employment or service with
Columbia/HCA or any related entity is to be credited as covered
employment or service for purposes of determining the vesting and
exercisability of such option (to the same extent as such period was
credited for such purposes under the related original Columbia/HCA
Option), and (b) in the case of any Columbia/HCA Non-Qualified Option,
the optionee is to be considered to be employed by or providing
services to the Corporation so long as he is employed by or providing
services to Columbia/HCA or LifePoint Hospitals, Inc. ("LifePoint")
(or any Subsidiary thereof), for purposes of determining when the
option will cease to be exercisable on account of termination of
employment or service, and at such time as the optionee ceases to be
employed by or provide services to Columbia/HCA or LifePoint (or any
Subsidiary thereof), such cessation of employment or service shall be
treated as though it were a cessation of employment or service with
the Corporation under comparable circumstances.
(v) For purposes hereof, the following definitions shall apply:
(a) "Affiliate" shall mean any entity required to be aggregated with
Columbia/HCA, LifePoint or Triad as appropriate, pursuant to Code
sections 414(b), 414(c), 414(m) or 414(o).
(b) "Columbia/HCA ISO" shall mean any option outstanding under a
Columbia/HCA Option Plan on the date of the Spin-off that is
intended to qualify as an "Incentive Stock Option" under section
422 of the Code.
(c) "Columbia/HCA Non-Qualified Option" shall mean any stock option
outstanding under a Columbia/HCA Option Plan on the date of the
Spin-off that is not a Columbia/HCA ISO. Any such option shall be
considered a "vested option" to the extent that it is exercisable
on the date in question and shall be considered a "non-vested
option" to the extent that it is not yet exercisable on such date.
(d) "Columbia/HCA Option" shall mean a Columbia/HCA ISO or Columbia/HCA
Non-Qualified Option, as the context shall indicate.
(e) "Columbia/HCA Option Plan" shall mean any plan maintained by
Columbia/HCA under which there are stock options outstanding on the
date of the Spin-off.
A-13
<PAGE>
(f) "Ex-Dividend Date" shall mean the first trading date on which the
Columbia/HCA stock shall trade on an ex-dividend basis with respect
to the distribution of the Corporation's Common Stock and
LifePoint's stock.
(g) "Original Number of Shares" shall mean, as to any Columbia/HCA
Option, the number of shares of Columbia/HCA stock covered by such
option immediately prior to the Spin-off.
(h) "Triad Business" shall mean any business conducted by Triad, or its
Subsidiaries, on the date of the Spin-off.
(i) "Triad Employee" shall mean an employee of the Corporation, or any
direct or indirect Subsidiary of the Corporation that is an
Affiliate thereof, on the date of the Spin-off.
(j) "Triad Ratio" shall mean a fraction whose numerator is the closing
price of the Common Stock on the trading date immediately preceding
the Ex-Dividend Date and whose denominator is the closing price of
the Columbia/HCA stock on such trading date immediately preceding
the Ex-Dividend Date.
(k) "Triad Share Multiple" shall mean the number of shares of Common
Stock to be distributed per share of Columbia/HCA stock on the date
of the Spin-off.
(l) "Triad Terminee" shall mean any individual who is no longer
employed by Columbia/HCA or any Affiliate thereof immediately prior
to the Spin-off but was employed by a Triad Business immediately
prior to his termination of employment from Columbia/HCA and its
Affiliates.
Notwithstanding anything elsewhere in the Plan to the contrary, the
Committee may grant Non-qualified Stock Options, effective as of the twenty-
first trading date for the Common Stock, at an exercise price equal to the Fair
Market Value of the Common Stock on such date, in accordance with the attached
Schedule and in accordance with such other terms as shall be established by the
Committee.
A-14
<PAGE>
EXHIBIT B
TRIAD HOSPITALS, INC.
EMPLOYEE STOCK PURCHASE PLAN
ARTICLE 1--Purpose
The Triad Hospitals, Inc. Employee Stock Purchase Plan (the "Plan") is
intended as an incentive and to encourage stock ownership by all eligible
employees of Triad Hospitals, Inc. (the "Company") and participating
subsidiaries so that they may share in the fortunes of the Company by acquiring
or increasing their proprietary interest in the Company. The Plan is designed
to encourage eligible employees to remain in the employ of the Company. It is
intended that options issued pursuant to this Plan shall constitute options
issued pursuant to an "employee stock purchase plan" within the meaning of
section 423 of the Internal Revenue Code of 1986, as amended (the "Code").
ARTICLE 2--Eligible Employees
All full-time and regular part-time employees of the Company (or of any of
its participating subsidiaries) who have completed three months of employment
with the Company (or any of its subsidiaries) shall be eligible to receive
options under this Plan to purchase shares of the common stock of the Company
(the "Common Stock") (except employees in countries whose laws make
participation impractical). Months of employment credited to otherwise eligible
employees of the Company for purposes of eligibility to participate in the
Columbia/HCA Healthcare Corporation Employee Stock Purchase Plan will be
credited solely for purposes of eligibility determinations in 1999 as months of
employment under the Plan. Persons who have been so employed for three months
or more (or otherwise credited with three or more months of employment) on the
first day of a Payment Period shall receive their options as of such day. In no
event may an employee be granted an option under the Plan if such employee,
immediately after the option is granted, owns stock representing five percent
(5%) or more of the total combined voting power or value of all classes of
stock of the Company. For purposes of determining stock ownership under this
Article, the rules of section 424(d) of the Code shall apply, and stock which
the employee may purchase under outstanding options shall be treated as stock
owned by the employee.
ARTICLE 3--Stock Subject to the Plan
The total number of shares of Common Stock of the Company that may be issued
pursuant to the Plan is 3,000,000 shares, which may consist, in whole or in
part, of unissued shares or treasury shares.
ARTICLE 4--Payment Periods and Stock Options
The six-month periods, December 1 to May 31 and June 1 to November 30, are
the Payment Periods during which payroll deductions will be accumulated under
the Plan; provided, however, the initial Payment Period shall be a special,
one-time, short period from July 1, 1999 to November 30, 1999. Each Payment
Period includes only regular paydays falling within it.
Two times each year, on the first business day of each Payment Period, the
Company will grant to each eligible employee who is then a participant in the
Plan an option to purchase on the last business day of such Payment Period, at
the Option Price, such number of shares of Common Stock reserved for the
purpose of the Plan which equals the number of whole or fractional shares whose
purchase price does not exceed ten percent (10%) of the participants Covered
Compensation during the Payment Period divided by the price as determined
below, on condition that such employee remains eligible to participate in the
Plan as provided herein. The participant shall be entitled to exercise such
options as granted only to the extent of his accumulated payroll deductions
through his last payday in a Payment Period.
B-1
<PAGE>
For purposes of the Plan, the "Option Price" for each Payment Period shall
be the lesser of (i) 85% of the average market price of the Company's Common
Stock on the first business day of the Payment Period, rounded up to avoid
fractions other than 1/4, 1/2, and 3/4, or (ii) 85% of the average market price
of the Company's Common Stock on the last business day of the Payment Period,
rounded up to avoid fractions other than 1/4, 1/2 and 3/4.
For purposes of the Plan, "Covered Compensation" means base compensation for
services, including shift or other regular compensatory premiums, and payments
in substitution for base pay, such as vacation, holiday, and sick pay, but not
including overtime, bonuses or short- or long-term disability payments.
For purposes of this Plan, the term "average market price" means the closing
price of Common Stock of the Company on the NASDAQ, or any other exchange upon
which the Company's Common Stock is then traded.
For purposes of this Plan, the term "business day" means a day on which
there is trading in the Company's Common Stock on the NASDAQ, or any other
exchange upon which the Company's Common Stock is then traded.
No employee shall be granted an option which permits his rights to purchase
Common Stock under the Plan and any similar plans of the Company (or any parent
or subsidiary corporations) to accrue at a rate which exceeds $25,000 of fair
market value of such stock (determined at the time such option is granted) for
each calendar year in which such option is outstanding at any time. The purpose
of the limitation in the preceding sentence is to comply with section 423(b)(8)
of the Code.
ARTICLE 5--Exercise of Option
Each eligible employee who continues to be a participant in the Plan on the
third Friday of the last month of a Payment Period shall be deemed to have
irrevocably stated his intention to exercise his option on the last business
day of such Payment Period and shall be deemed to have purchased from the
Company the number of such whole or fractional shares of Common Stock reserved
for the purposes of the Plan as his accumulated payroll deductions during such
Payment Period will purchase at the Option Price. If a participant is not an
employee on the third Friday of the last month of a Payment Period, he shall
not be entitled to exercise his option.
ARTICLE 6--Authorization for Entering Plan
An employee may become a participant in the Plan by filling out, signing and
delivering to the Company's Human Resources Department an Authorization in the
form and manner satisfactory to the Company:
A. stating the whole percentage of Covered Compensation to be deducted
regularly from his pay; and
B. authorizing the purchase of Common Stock for him in each Payment Period
in accordance with the terms of the Plan.
Such Authorization must be received by the Company's Human Resources
Department no later than the third Friday of the last month of a Payment Period
in order to be effective for the following Payment Period.
The Company will accumulate and hold for the employee's account the amounts
deducted from his pay pursuant to his Authorization. No interest will be paid
on such amounts.
ARTICLE 7--Amount of Payroll Deductions
An employee may authorize payroll deductions in a whole percentage amount
not less than one percent (1%) but not more than ten percent (10%) of his
Covered Compensation received during the Payment Period.
B-2
<PAGE>
ARTICLE 8--Change in Payroll Deductions
Deductions may be increased or decreased only at the beginning of a Payment
Period. A new Authorization will be required and must be received by the
Company's Human Resources Department no later than the third Friday of the last
month of a Payment Period in order to be effective for the following Payment
Period.
ARTICLE 9--Withdrawal from the Plan
An employee may withdraw from the Plan, in whole but not in part, at any
time by delivering an Authorization to the Company's Human Resources Department
indicating such employee's intent to withdraw. An employee may change his
contribution rate effective the first day of a Payment Period. Once during each
Payment Period, an employee may reduce his contribution rate to 0% and may
either allow dollars contributed to participate in the allocation or receive a
refund prior to the allocation. If such Authorization is received at least five
(5) business days prior to the third Friday of the last month of a Payment
Period, the Company will promptly refund the entire balance of his deductions
accumulated during such period. If an employee's Authorization is received
after such date, but before the end of a Payment Period, deductions will be
stopped as soon as practicable, and deductions accumulated during such period
will be applied to the purchase of stock.
An employee who withdraws from the Plan is like an employee who has never
entered the Plan. To re-enter, he must file a new Authorization by the third
Friday of the last month of a Payment Period which cannot, however, become
effective before the beginning of the next Payment Period following his
withdrawal.
ARTICLE 10--Establishment of Brokerage Account
By enrolling in the Plan, each participating employee will be deemed to have
authorized the establishment of a brokerage account in his name at a securities
brokerage firm approved by the Compensation Committee of the Company's Board of
Directors (the "Committee").
ARTICLE 11--Issuance of Stock; Fractional Shares
Stock purchased under the Plan will be held in an account in the name of the
employee, or if his Authorization so specifies, in the name of the employee and
another person of legal age as joint tenants with rights of survivorship,
unless prohibited by state law. Certificates will be issued, at the employee's
request, only for whole numbers of shares. Fractional interests in shares will
be carried forward in an employee's account until such time as they equal one
full share, or until the termination of an employee's brokerage account,
whereupon an amount equal to the value of such fractional interest shall be
paid in cash to the employee.
ARTICLE 12--No Transfer or Assignment of Employee's Rights
An employee's rights under the Plan are his alone and may not be
transferred, assigned to or availed of by any other person. Any option granted
to an employee may be exercised only by him.
ARTICLE 13--Termination of Employee's Rights
An employee's rights under the Plan will terminate when he ceases to be an
employee because of retirement, resignation, discharge, death, change of
status, or for any other reason. A withdrawal Authorization will be considered
as having been received from the employee on the day his employment ceases, and
all payroll deductions not used to purchase stock will be refunded to the
employee, or in the event of the employee's death, to his estate.
If an employee's payroll deductions are interrupted by any legal process, a
withdrawal Authorization will be considered as having been received from him on
the day the interruption occurs.
B-3
<PAGE>
ARTICLE 14--Termination and Amendments to the Plan
The Plan may be terminated at any time by the Committee. It will terminate
in any case when all or substantially all of the shares of stock reserved for
the purposes of the Plan have been purchased. If at any time shares of stock
reserved for the purpose of the Plan remain available for purchase but not in
sufficient number to satisfy all then unfilled purchase requirements, the
available shares shall be apportioned among participants in proportion to their
options, and the Plan shall terminate. Upon such termination or any other
termination of the Plan, all payroll deductions not used to purchase stock will
be refunded.
The Committee also reserves the right to amend the Plan from time to time in
any respect; provided, however, that no amendment shall be effective without
prior approval of the stockholders of the Company, which would (a) except as
provided in Article 21, increase the number of shares of Common Stock to be
offered above or (b) except as provided in Article 17, change the classes of
employees eligible to receive options under the Plan.
ARTICLE 15--Limitations on Sale of Stock Purchased Under the Plan
The Plan is intended to provide Common Stock for investment and not for
resale. The Company does not, however, intend to restrict or influence any
employee in the conduct of his own affairs. An employee may, therefore, sell
stock purchased under the Plan at any time he chooses; provided, however, that
because of certain federal income tax requirements, each employee will agree by
entering the Plan, to give the Company prompt notice of any such stock disposed
of within (i) two years after the date of grant of the applicable option or
(ii) one year after the transfer of such stock to such employee showing the
number of such shares disposed of, and an appropriate legend requiring such
notice shall be placed on the certificates of Common Stock issued hereunder.
The employee assumes the risk of any market fluctuations in the price of such
stock.
ARTICLE 16--Company's Payment of Expenses Related to the Plan
The Company will bear all costs of administering and carrying out the Plan.
ARTICLE 17--Participating Subsidiaries
The term "participating subsidiaries" shall mean any subsidiary of the
Company (i) which is at least fifty percent (50%) owned by the Company (or a
parent or a subsidiary), (ii) which is a "corporation" as determined under
section 424 of the Code and (iii) which is designated by the Committee to
participate in the Plan. The Committee shall have the power to make such
designation before or after the Plan is approved by the stockholders.
ARTICLE 18--Administration of the Plan
The Plan shall be administered by the Committee. Acts by a majority of the
Committee, or acts reduced to or approved in writing by a majority of the
members of the Committee, shall be the valid acts of the Committee.
The interpretation and construction by the Committee of any provisions of
the Plan or of any option granted under it shall be final. The Committee may
from time to time adopt such rules and regulations for carrying out the Plan as
it may deem best. No member of the Board of Directors or the Committee shall be
liable for any action or determination made in good faith with respect to the
Plan or any option granted under it.
ARTICLE 19--Optionees Not Stockholders
Neither the granting of an option to an employee nor the deductions from his
pay shall make such employee the owner of the shares covered by an option until
such shares have been purchased by him.
B-4
<PAGE>
ARTICLE 20--Application of Funds
The proceeds received by the Company from the sale of Common Stock pursuant
to options granted under the Plan will be used for general corporate purposes.
ARTICLE 21--Changes in Capital
If the Common Stock of the Company subject to the Plan shall at any time be
changed or exchanged by declaration of a stock dividend, stock split,
combination of shares, recapitalization, merger, consolidation or other
corporate reorganization in which the Company is the surviving corporation, the
number and kind of shares subject to this Plan and the option prices shall be
appropriately and equitably adjusted so as to maintain the option prices
thereof. In the event of a dissolution or liquidation of the Company or a
merger, consolidation, sale of all or substantially all of its assets, or other
corporate reorganization in which the Company is not the surviving corporation,
or any merger in which the Company is the surviving corporation but the holders
of its Common Stock receive securities of another corporation, any outstanding
options hereunder shall terminate. The existence of the Plan or options
hereunder shall not in any way prevent any transaction described herein, and no
holder of an option shall have the right to prevent such transaction.
ARTICLE 22--Approval of Stockholders
Commencement of the Plan shall be subject to approval by the stockholders of
the Company within 12 months before or after the date the Plan is adopted by
the Board of Directors. Notwithstanding any provision to the contrary, failure
to obtain such stockholder approval shall void the Plan, any options granted
under the Plan, any share purchases pursuant to the Plan, and all rights of all
participants.
B-5
<PAGE>
FOLD AND DETACH HERE
- --------------------------------------------------------------------------------
PROXY PROXY
TRIAD HOSPITALS, INC.
Proxy For Annual Meeting on May 23, 2000
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
The undersigned hereby appoints Donald P. Fay and Burke W. Whitman proxies,
each with the power to appoint his substitute and with authority in each to act
in the absence of the other, to represent and to vote all shares of stock of
Triad Hospitals, Inc. which the undersigned is entitled to vote at the Annual
Meeting of Stockholders of Triad Hospitals, Inc. to be held at the Westin Park
Central Hotel, 8051 LBJ Freeway, Dallas, Texas, on Tuesday, May 23, 2000 at
10:00 a.m., local time, and any adjournments thereof, as indicated on the
proposals described in the Proxy Statement, and all other matters properly
coming before the meeting.
IMPORTANT--This Proxy Must Be Signed And Dated On The Reverse Side.
THIS PROXY WILL BE VOTED IN ACCORDANCE WITH SPECIFICATIONS MADE. IF NO CHOICES
ARE INDICATED, THIS PROXY WILL BE VOTED FOR ITEMS 1 THROUGH 4.
Please sign exactly as your name or names appear hereon. For joint accounts,
both owners should sign. When signing as executor, administrator, attorney,
trustee or guardian, etc., please give your full title.
<PAGE>
FOLD AND DETACH HERE
- --------------------------------------------------------------------------------
Triad Hospitals, Inc.
PLEASE MARK VOTE IN BOX IN THE FOLLOWING MANNER USING DARK INK ONLY
A vote FOR Items 1 through 4 is recommended by the Board of Directors
---
1. Election of Directors Marvin Runyon, Dale V. Kesler, Barbara A. Durand, R.N.
and Donald B. Halverstadt, M.D.
[_] For All [_] Withhold All [_] For All Except
Instruction: To withhold authority to vote for an individual nominee, write that
nominee's name in the following space:
- --------------------------------------------------------------------------------
2. Ratification of PricewaterhouseCoopers LLP as independent auditors.
[_] FOR [_] AGAINST [_] ABSTAIN
3. Approval of 1999 Long-Term Incentive Plan.
[_] FOR [_] AGAINST [_] ABSTAIN
4. Approval of Employee Stock Purchase Plan.
[_] FOR [_] AGAINST [_] ABSTAIN
Dated: , 2000
---------------------
--------------------------------
Signature
--------------------------------
Signature if held jointly
<PAGE>
TRIAD HOSPITALS, INC.
ANNUAL MEETING OF STOCKHOLDERS
MAY 23, 2000
VOTING INSTRUCTION FORM
Voting Instruction Solicited by the Trustee of
Triad Hospitals Employee Stock Ownership Trust
The undersigned participant in the Triad Hospitals, Inc. Retirement Savings
Plan (the "Plan") hereby instructs U.S. Trust Company, N.A., as Trustee of the
Triad Hospitals, Inc. Employee Stock Ownership Trust, to vote at the Annual
Meeting of Stockholders on May 23, 2000 or any adjournment thereof, all shares
of Common Stock that have been allocated to the account of the undersigned on
the Proposals more fully described in enclosed the Proxy Statement.
THIS FORM MUST BE PROPERLY COMPLETED, SIGNED, DATED AND RECEIVED BY THE
TRUSTEE NO LATER THAN 5:00 P.M. EASTERN TIME ON WEDNESDAY, MAY 17, 2000. IF
YOUR VOTING INSTRUCTIONS ARE NOT TIMELY RECEIVED, THE TRUSTEE WILL VOTE YOUR
SHARES IN THE SAME MANNER AND PROPORTION AS THOSE SHARES FOR WHICH INSTRUCTIONS
ARE TIMELY RECEIVED. YOUR VOTING INSTRUCTIONS TO THE TRUSTEE ARE
CONFIDENTIAL, AS EXPLAINED IN THE ACCOMPANYING NOTICE TO PLAN PARTICIPANTS.
<TABLE>
<S> <C> <C> <C>
[X] Please mark your choice like this and sign and date below.
FOR the election of directors listed: Marvin Runyon, For Withhold For All
Dale V. Kesler, Barbara A. Durand, R.N., and All All Except
Donald B. Halverstadt, M.D. [_] [_] [_]
WITHHOLD AUTHORITY: to withhold authority to
vote for an individual nominee, write that nominee's
name in the following space:
2. Ratification of PricewaterhouseCoopers, LLP as For Against Abstain
independent auditors. [ ] [ ] [ ]
3. Approval of Long-Term Incentive Plan. For Against Abstain
[ ] [ ] [ ]
4. Approval of Employee Stock Purchase Plan. For Against Abstain
[ ] [ ] [ ]
</TABLE>
As a Participant in the Plan, I hereby acknowledge receipt of the Notice to
Participants and the accompanying Proxy Statement relating to the Annual Meeting
of Stockholders of Triad Hospitals, Inc., and hereby instruct the Trustee to
vote all shares credited to my Plan account as I have indicated above. If I
sign, date and return this form but do not specifically instruct the Trustee how
to vote, I understand that the Trustee will vote the shares credited to my
account in the same manner and proportion as those Shares for which timely
instructions from participants were received.
Signature: Date:
----------------------------------- ---------------
